



US 20080280325A1

(19) **United States**

(12) **Patent Application Publication**  
**Johansen et al.**

(10) **Pub. No.: US 2008/0280325 A1**

(43) **Pub. Date: Nov. 13, 2008**

(54) **POLYPEPTIDES HAVING ENDOGLUCANASE  
ACTIVITY AND POLYNUCLEOTIDES  
ENCODING SAME**

**Related U.S. Application Data**

(60) Provisional application No. 60/738,430, filed on Nov. 21, 2005.

(76) Inventors: **Katja Salomon Johansen**, Gentofte (DK); **Keith Gibson**, Bagsvaerd (DK); **Preben Nielsen**, Hoersholm (DK); **Helle Outtrup**, Vaerloese (DK)

(30) **Foreign Application Priority Data**

Nov. 16, 2005 (DK) ..... PA 2005 01599

**Publication Classification**

(51) **Int. Cl.**  
*C12P 21/04* (2006.01)  
*C12N 9/42* (2006.01)  
*C11D 7/42* (2006.01)  
*C12N 15/11* (2006.01)  
*C12N 15/00* (2006.01)  
*C12N 1/20* (2006.01)

Correspondence Address:  
**NOVOZYMES NORTH AMERICA, INC.**  
**500 FIFTH AVENUE, SUITE 1600**  
**NEW YORK, NY 10110 (US)**

(52) **U.S. Cl.** ..... 435/69.1; 435/209; 510/392; 435/267; 536/23.2; 435/320.1; 435/252.33

(21) Appl. No.: **12/090,400**

(57) **ABSTRACT**

(22) PCT Filed: **Nov. 15, 2006**

The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

(86) PCT No.: **PCT/EP2006/068509**

§ 371 (c)(1),  
(2), (4) Date: **Apr. 16, 2008**




Figure 1A

```

-----+-----+-----+-----+-----+
          10          20          30          40          50
-----+-----+-----+-----+-----+
1  -----VRQPIGKKIIAAGMIFTLLESLIV----- ACE160
1  MKIKQIKQSLSLLLIIT-LIMSLFVPMASANTNESKSNAFPFSVDVKKTSW KSM634
1  MKIKQIKQSLSLLLIIT-LIMSLFVPMASANTNESKSNAFPFSVDVKKTSW KSM365
1  MKIKQIKQSLSLLLIIT-LIMSLFVPMASANTNESKSNAFPFSVDVKKTSW KSM635
1  ----MMLRKKTKQLISSILILVLLLSLFP----- KSM64
1  ----MMLRKKTKQLISSILILVLLLSLFP----- KSM-S237
1  ----- MB1181

-----+-----+-----+-----+-----+
          60          70          80          90          100
-----+-----+-----+-----+-----+
25  -----TVFPTAGQALES---DY ACE160
50  SFPYIKDLYEQEVITGTSATTFSP TDSVTRAQFTVMLTRGLGLEASSKDY KSM634
50  SFPYIKDLYEQEVITGTSATTFSP TDSVTRAQFTVMLTRGLGLEASSKDY KSM365
50  SFPYIKDLYEQEVITGTSATTFSP TDSVTRAQFTVMLTRGLGLEASSKDY KSM635
26  -----TALAAEGNTRED---NF KSM64
26  -----AALAAEGNTRED---NF KSM-S237
1  -----AEGNTRED---NF MB1181

-----+-----+-----+-----+-----+
          110          120          130          140          150
-----+-----+-----+-----+-----+
39  SHLLGN----DAVKRPSE-----G-----GALS---- ACE160
100 PFKDRKNWAYKEIQAA YEAGIVTGKTNGEFAPNENITREQMAAMAVRAYE KSM634
100 PFKDRKNWAYKEIQAA YEAGIVTGKTNGEFAPNENITREQMAAMAVRAYE KSM365
100 PFKDRKNWAYKEIQAA YEAGIVTGKTNGEFAPNENITREQMAAMAVRAYE KSM635
40  KHLLGN----DNVKRPSE----- KSM64
40  KHLLGN----DNVKRPSE----- KSM-S237
11  KHLLGN----DNVKRPSE----- MB1181

```

Figure 1B

```

-----+-----+-----+-----+-----+
          160       170       180       190       200
-----+-----+-----+-----+-----+
58 -LCNETTP-----VK-----PNH ACE160
150 YLENELSLPEEQREYNDSSSISTFAQDAVQKAYVLELMEGNTDGYFQPKR KSM634
150 YLENELSLPEEQREYNDSSSISTFAQDAVQKAYVLELMEGNTDGYFQPKR KSM365
150 YLENELSLPEEQREYNDSSSISTFAQDAVQKAYVLELMEGNTDGYFQPKR KSM635
54 ----- KSM64
54 ----- KSM-S237
25 ----- MB1181

-----+-----+-----+-----+-----+
          210       220       230       240       250
-----+-----+-----+-----+-----+
70 AGDRGKP-----S-----HAGK GK-PPHAGKPEHAGPK-RKTL ACE160
200 NSTREQSAKVISTLLWKVASHDYLYHTEAVKSPSEAGALQLVELNGQLTL KSM634
200 NSTREQSAKVISTLLWKVASHDYLYHTEAVKSPSEAGALQLVELNGQLTL KSM365
200 NSTREQSAKVISTLLWKVASHDYLYHTEAVKSPSEAGALQLVELNGQLTL KSM635
54 -----AGALQLQEVDGQMTL KSM64
54 -----AGALQLQEVDGQMTL KSM-S237
25 -----AGALQLQEVDGQMTL MB1181

-----+-----+-----+-----+-----+
          260       270       280       290       300
-----+-----+-----+-----+-----+
101 CDATGSQIQLRGMSTHGLQWFGEIINDNAFAALSNDWEANMIRLAMYIGE ACE160
250 AGEDGTPVQLRGMSTHGLQWFGEIVNENAFVALSNDWGSNMIRLAMYIGE KSM634
250 AGEDGTPVQLRGMSTHGLQWFGEIVNENAFVALSNDWGSNMIRLAMYIGE KSM365
250 AGEDGTPVQLRGMSTHGLQWFGEIVNENAFVALSNDWGSNMIRLAMYIGE KSM635
69 VDQHGEKIQLRGMSTHGLQWFPEILNDNAYKALANDWESNMIRLAMYVGE KSM64
69 VDQHGEKIQLRGMSTHGLQWFPEILNDNAYKALSNDWDSNMIRLAMYVGE KSM-S237
40 VDQHGEKIQLRGMSTHGLQWFPEILNDNAYKALANDWESNMIRLAMYVGE MB1181

```



Figure 1C

	310	320	330	340	350	
151	NGYATNP-EVKELVYEGIELAFK	HDMYVI	VDWHVHAPGDPRADIYSGALD			ACE160
300	NGYATNP-EVKDLVYEGIELAFEH	HDMYVI	VDWHVHAPGDPRADVYSGAYD			KSM634
300	NGYATNP-EVKDLVYEGIELAFEH	HDMYVI	VDWHVHAPGDPRADVYSGAYD			KSM365
300	NGYATNP-EVKDLVYEGIELAFEH	HDMYVI	VDWHVHAPGDPRADVYSGAYD			KSM635
119	NGYASNPELIKSRVIKIDLAIEND	MYVI	VDWHVHAPGDPRDPVYAGAED			KSM64
119	NGYATNPPELIKQRVIDGIELAI	ENDMYVI	VDWHVHAPGDPRDPVYAGAKD			KSM-S237
90	NGYASNPELIKSRVIKIDLAIEND	MYVI	VDWHVHAPGDPRDPVYAGAED			MB1181
	360	370	380	390	400	
200	FFKEIADHYKDHPKFHYIIWEI	ANEPSP	NNSGGPGIPNDETGWKAVKEYA			ACE160
349	FFEEIADHYKDHPKNHYIIWEL	ANEPSP	NNNGGPGLTNDEKGEAVKEYA			KSM634
349	FFEEIADHYKDHPKNHYIIWEL	ANEPSP	NNNGGPGLTNDEKGEAVKEYA			KSM365
349	FFEEIADHYKDHPKNHYIIWEL	ANEPSP	NNNGGPGLTNDEKGEAVKEYA			KSM635
169	FFRDIAALYPNNP---HI	IYELAN	EPSSNNGGAGIPNNEEGWNAVKEYA			KSM64
169	FFREIAALYPNNP---HI	IYELAN	EPSSNNGGAGIPNNEEGWKAVKEYA			KSM-S237
140	FFRDIAALYPNNP---HI	IYELAN	EPSSNNGGAGIPNNEEGWNAVKEYA			MB1181
	410	420	430	440	450	
250	EPIVEMLRERG---DNI	ILVGSP	NWSQRPDLAADNPIDAKNIMYSVHFYT			ACE160
399	EPIVEMLRKRG---DNM	ILVGSP	NWSQRPDLSADNPIDAENIMYSVHFYT			KSM634
399	EPIVEMLRKRG---DNM	ILVGSP	NWSQRPDLSADNPIDAENIMYSVHFYT			KSM365
399	EPIVEMLRKRG---DNM	ILVGSP	NWSQRPDLSADNPIDAENIMYSVHFYT			KSM635
216	DPIVEMLRDSGNADDNII	IVGSP	NWSQRPDLAADNPIDDHHTMYTVHFYT			KSM64
216	DPIVEMLRKSGNADDNII	IVGSP	NWSQRPDLAADNPIDDHHTMYTVHFYT			KSM-S237
187	DPIVEMLRDSGNADDNII	IVGSP	NWSQRPDLAADNPINDHHTMYTVHFYT			MB1181

Figure 1D

	460	470	480	490	500	
297	GSHEPSDTSYPEGTPSSERNV	MANVRYALENGAAVFATEW	GTSQANGDG			ACE160
446	GSHGASHIGYPEGTPSSERS	NVMANVLLDNGVAVFATEW	GTSQANGDG			KSM634
446	GSHGASHIGYPEGTPSSERS	NVMANVRYALDNGVAVFATEW	GTSQANGDG			KSM365
446	GSHGASHIGYPEGTPSSERS	NVMANVRYALDNGVAVFATEW	GTSQANGDG			KSM635
266	GSHAASTESYPPETPNSE	RGNVMSNTRYALENGVAVFATEW	GTSQANGDG			KSM64
266	GSHAASTESYPSETPNSE	RGNVMSNTRYALENGVAVFATEW	GTSQASGDG			KSM-S237
237	GSHAASTESYPPETPNSE	RGNVMSNTRYALENGVAVFATEW	GTSQANGDG			MB1181
	510	520	530	540	550	
347	GPYLDEADVWLNFLNENN	ISWVNWSLTNKNETSGSFT	PFELGKSNATSLD			ACE160
496	GPYFDEADVWLNFLNKHN	ISWANWSLTNKNEISGAFT	PFELGRTDATDLD			KSM634
496	GPYFDEADVWLNFLNKHN	ISWANWSLTNKNEISGAFT	PFELGRTDATDLD			KSM365
496	GPYFDEADVWLNFLNKHN	ISWANWSLTNKNEISGAFT	PFELGRTDATDLD			KSM635
316	GPYFDEADVWIEFLNENN	ISWANWSLTNKNEVSGAFT	PFELGKSNATSLD			KSM64
316	GPYFDEADVWIEFLNENN	ISWANWSLTNKNEVSGAFT	PFELGKSNATNLD			KSM-S237
287	GPYFDEADVWIEFLNENN	ISWANWSLTNKNEVSGAFT	PFELGKSNATNLD			MB1181
	560	570	580	590	600	
397	PGPEQAWSLPELSVSGEY	VRSRIKGSPEYEPDR	TKFNKVIWDFNDG	TVQG		ACE160
546	PGANQVWAPEELSLSGEY	VRARIKGIETYTPIDR	TKFTKLWDFNDG	TTQG		KSM634
546	PGANQVWAPEELSLSGEY	VRARIKGIETYTPIDR	TKFTKLWDFNDG	TTQG		KSM365
546	PGANQVWAPEELSLSGEY	VRARIKGIETYTPIDR	TKFTKLWDFNDG	TTQG		KSM635
366	PGPDQVWVPEELSLSGEY	VRARIKGVNYEPIDR	TKYTKVLWDFNDG	TKQG		KSM64
366	PGPDHVWAPEELSLSGEY	VRARIKGVNYEPIDR	TKYTKVLWDFNDG	TKQG		KSM-S237
337	PGPDHVWAPEELSLSGEY	VRARIKGVNYEPIDR	TKYTKVLWDFNDG	TKQG		MB1181



Figure 1E

	610	620	630	640	650	
447	FEVNDDSPVKEEIAVSNAGNALQITGLNASNDISTDNFWSNLRLSANSWG					ACE160
596	FQVNGDSPNKESITLSNNDALQIEGLNVSNDISEGNYWDNVRLSADGWS					KSM634
596	FQVNGDSPNKESITLSNNDALQIEGLNVSNDISEGNYWDNVRLSADGWS					KSM365
596	FQVNGDSPNKESITLSNNDALQIEGLNVSNDISEGNYWDNVRLSADGWS					KSM635
416	FGVNGDSP-VEDVVIENEAGALKLSGLDASNDVSEGNYWANARLSADGWS					KSM64
416	FGVNSDSPNKELIAVDNENNTLKVSGLDVSDGNFWANARLSANGWG					KSM-S237
387	FGVNSDSPNKELIAVDNENNTLKVSGLDVSDGNFWANARLSADGWS					MB1181
	660	670	680	690	700	
497	ESVNILGAEELTLDVIVDEPTSVSIAAIPQSAAVGWANPNNAVVSKEDE					ACE160
646	ENVDILGATELTIDVIVEEPTTVSIAAIPQGPAGWANPTRAIKVTEDDF					KSM634
646	ENVDILGATELTIDVIVEEPTTVSIAAIPQGPAGWANPTRAIKVTEDDF					KSM365
646	ENVDILGATELTIDVIVEEPTTVSIAAIPQGPAGWANPTRAIKVTEDDF					KSM635
465	KVDILGAEKLTMDVIVDEPTTVSIAAIPQGPSANWVNPRAIKVEPTNF					KSM64
466	KVDILGAEKLTMDVIVDEPTTVSIAAIPQSSKSGWANPERAVRVNAEDF					KSM-S237
437	KVDILGAEKLTMDVIVDEPTTVSIAAIPQSSKSGWANPERAVRVNAEDF					MB1181
	710	720	730	740	750	
547	APYGG-QYKAVLTITPEDSPALGAIATHSDDNMNNIILFIGTENADVLS					ACE160
696	ESFGD-GYKALVTITSEDSPTSLETIATSPEDNTMSNIILFVGTEADVIS					KSM634
696	ESFGD-GYKALVTITSEDSPTSLETIATSPEDNTMSNIILFVGTEADVIS					KSM365
696	ESFGD-GYKALVTITSEDSPTSLETIATSPEDNTMSNIILFVGTEADVIS					KSM635
515	VPLGD-KFKAELTITSADSPSLEAIAMHAENNNINNIILFVGTEGADVIY					KSM64
516	VQQTGKYKAGLTITGEDAPNLKNIAFHEEDNNMNNIILFVGTDAAADVIY					KSM-S237
487	VQQTGKYKAGLTITGEDAPNLKNIAFHEEDNNMNNIILFVGTDAAADVIY					MB1181

Figure 1F


	-----+-----+-----+-----+-----+-----	
	760            770            780            790            800	
	-----+-----+-----+-----+-----+-----	
596	LDNITVKGSIVEIPVIHDPKGI AVLPSNFEDGTRQGDWNPESGVKTALT	ACE160
745	LDNITVSGTEIEIEVIHDEKGTATLPSTFEDGTRQGDWHTESGVKTALT	KSM634
745	LDNITVSGTEIEIEVIHDEKGTATLPSTFEDGTRQGDWHTESGVKTALT	KSM365
745	LDNITVSGTEIEIEVIHDEKGTATLPSTFEDGTRQGDWHTESGVKTALT	KSM635
564	LDNIKVIGTEVEIPVVHDPKGEAVLPSVFEDGTRQGDWAGESGVKTALT	KSM64
566	LDNIKVIGTEVEIPVVHDPKGEAVLPSVFEDGTRQGDWAGESGVKTALT	KSM-S237
537	LDNIKVIGTEVEIPVVHDPKGEAVLPSVFEDGTRQGDWAGESGVKTALT	MB1181
	-----+-----+-----+-----+-----+-----	
	810            820            830            840            850	
	-----+-----+-----+-----+-----+-----	
646	IKEADGSHALSWEFAYPEVKPGDGWATAPRLEFWKDGLVRGANDYLSFDL	ACE160
795	IEEANGSNALSWEYAYPEVKPSDGWATAPRLDFWKDELVRGTSDYISFDF	KSM634
795	IEEANGSNALSWEYAYPEVKPSDGWATAPRLDFWKDELVRGTSDYISFDF	KSM365
795	IEEANGSNALSWEYAYPEVKPSDGWATAPRLDFWKDELVRGTSDYISFDF	KSM635
614	IEEANGSNALSWEFGYPEVKPSDNWATAPRLDFWKSDDLVRGENDYVTFDF	KSM64
616	IEEANGSNALSWEFGYPEVKPSDNWATAPRLDFWKSDDLVRGENDYVAFDF	KSM-S237
587	IEEANGSNALSWEFGYPEVKPSDNWATAPRLDFWKSDDLVRGENDYVAFDF	MB1181
	-----+-----+-----+-----+-----+-----	
	860            870            880            890            900	
	-----+-----+-----+-----+-----+-----	
696	YLDPVRATEGAIITTHLVFQPPSAGYWVQAPASHSIDLLNLD SADITADGL	ACE160
845	YIDAVRASEGAISINAVFQPPANGYWQEVPTTFEIDLTELDSATVTSDEL	KSM634
845	YIDAVRASEGAISINAVFQPPANGYWQEVPTTFEIDLTELDSATVTSDEL	KSM365
845	YIDAVRASEGAISINAVFQPPANGYWQEVPTTFEIDLTELDSATVTSDEL	KSM635
664	YLDPVRATEGAMNINLVFQPPTNGYWVQAPKTYTINFDELEEAN-QVNGL	KSM64
666	YLDPVRATEGAMNINLVFQPPTNGYWVQAPKTYTINFDELEEAN-QVNGL	KSM-S237
637	YLDPVRATEGAMNINLVFQPPTNGYWVQAPKTYTINFDELEEAN-QVNGL	MB1181

Figure 1G

	-----+	-----+	-----+	-----+	-----+
	910	920	930	940	950
	-----+	-----+	-----+	-----+	-----+
746	YHYEVKFNIRDITAIQDDTALRNMILILEDRNSDFAGRAFIDNVRFE.				ACE160
895	YHYEVKINIRDIEAITDDTELRLNLLLI FADESDFAGRVFVDNVRFE				KSM634
895	YHYEVKINIRDIEAITDDTELRLNLLLI FADESDFAGRVFVDNVRFE				KSM365
895	YHYEVKINIRDIEAITDDTELRLNLLLI FADESDFAGRVFVDNVRFE				KSM635
713	YHYEVKINVRDITNIQDDTLRLNMMIIFADVESDFAGRVFVDNVRFE				GAA KSM64
715	YHYEVKINVRDITNIQDDTLRLNMMIIFADVESDFAGRVFVDNVRFE				GAA KSM-S237
686	YHYEVKINVRDITNIQDDTLRLNMMIIFADVESDFAGRVFVDNVRFE				GAA MB1181
	-----+	-----+	-----+	-----+	-----+
	960	970	980	990	1000
	-----+	-----+	-----+	-----+	-----+
793					ACE160
941					KSM634
941					KSM365
941					KSM635
763	TTEPVEPEPVDPGEETPPVDEKEAKKEQKEAEKEEKEAVKEEKKEAKEEK				KSM64
765	TTEPVEPEPVDPGEETPPVDEKEAKKEQKEAEKEEKEAVKEEKKEAKEEK				KSM-S237
736	TTEPVEPEPVDPGEETPPVDEKEAKKEQKEAEKEEKEE				MB1181
	-----+				
	1010				
	-----+				
793					ACE160
941					KSM634
941					KSM365
941					KSM635
813	KAIKNEATKK				KSM64
815	KAVKNEAKKK				KSM-S237
773					MB1181



Figure 2



**POLYPEPTIDES HAVING ENDOGLUCANASE  
ACTIVITY AND POLYNUCLEOTIDES  
ENCODING SAME**

SEQUENCES

**[0001]** SEQ ID NO:1, Polynucleotide sequence encoding *Bacillus* sp. ACE160 endoglucanase.  
SEQ ID NO:2, Polypeptide sequence of *Bacillus* sp. ACE160 endoglucanase and carbohydrate binding module.

FIELD OF THE INVENTION

**[0002]** The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides in the detergent, paper and pulp, oil drilling, oil extraction, wine and juice, food ingredients, animal feed or textile industries.

BACKGROUND OF THE INVENTION

**[0003]** Cellulose is a polymer of glucose linked by beta-1,4-glucosidic bonds. Cellulose chains form numerous intra- and intermolecular hydrogen bonds, which result in the formation of insoluble cellulose micro-fibrils. Microbial hydrolysis of cellulose to glucose involves the following three major classes of cellulases: (i) endo-glucanases (EC 3.2.1.4) which cleave beta-1,4-glucosidic links randomly throughout cellulose molecules, also called endo-beta-1,4-glucanases; (ii) cellobiohydrolases (EC 3.2.1.91) which digest cellulose from the non-reducing end, releasing cellobiose; and (iii) beta-glucosidases (EC 3.2.1.21) which hydrolyse cellobiose and low molecular-weight celloextrins to release glucose.

**[0004]** Beta-1,4-glucosidic bonds are also present in other naturally occurring polymers, e.g. in the beta-glucans from plants such as barley and oats. In some cases, endoglucanases also provide hydrolysis of such non-cellulose polymers.

**[0005]** Cellulases are produced by many micro-organisms and are often present in multiple forms. Recognition of the economic significance of the enzymatic degradation of cellulose has promoted an extensive search for microbial cellulases, which can be used industrially. As a result, the enzymatic properties and the primary structures of a large number of cellulases have been investigated. On the basis of the results of a hydrophobic cluster analysis of the amino acid sequence of the catalytic domain, these cellulases have been placed into different families of glycosyl hydrolases; fungal and bacterial glycosyl hydrolases have been grouped into 35 families (Henrissat, B.: A classification of glycosyl hydrolases based on amino acid sequence similarities. *Biochem. J.* 280 (1991), 309-316. Henrissat, B., and Bairoch, A.: New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. *Biochem. J.* 293 (1993), 781-788.). Most cellulases consist of a carbohydrate binding module (CBM) and a catalytic domain (CAD) separated by a linker which may be rich in proline and hydroxy amino acid residues. Another classification of cellulases has been established on the basis of the similarity of their CBMs (Gilkes et al. (1991)) giving five families of glycosyl hydrolases (I-V).

**[0006]** Cellulases are synthesized by a large number of microorganisms which include fungi, actinomycetes, myxobacteria and true bacteria but also by plants. Especially endo-beta-1,4-glucanases of a wide variety of specificities have

been identified. Many bacterial endo-glucanases have been described (Gilbert, H. J. and Hazlewood, G. P. (1993) *J. Gen. Microbiol.* 139:187-194. Henrissat, B., and Bairoch, A.: New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. *Biochem. J.* 293 (1993), 781-788.).

**[0007]** An important industrial use of cellulolytic enzymes is for treatment of paper pulp, e.g. for improving the drainage or for de-inking of recycled paper. Another important industrial use of cellulolytic enzymes is for treatment of cellulosic textile or fabrics, e.g. as ingredients in detergent compositions or fabric softener compositions, for bio-polishing of new fabric (garment finishing), and for obtaining a "stone-washed" look of cellulose-containing fabric, especially denim, and several methods for such treatment have been suggested, e.g. in GB-A-1 368 599, EP-A-0 307 564 and EP-A-0 435 876, WO 91/17243, WO 91/10732, WO 91/17244, WO 95/24471 and WO 95/26398. JP patent application no. 13049/1999 discloses a heat resistant alkaline cellulase derived from *Bacillus* sp. KSM-S237 (deposited as FERM-P-16067) suitable for detergents.

**[0008]** There is an ever existing need for providing novel cellulase enzymes or enzyme preparations which may be used for applications where cellulase, preferably an endo-beta-1,4-glucanase, activity (endoglucanase, EC 3.2.1.4) is desirable.

**[0009]** The object of the present invention is to provide polypeptides and polypeptide compositions having substantial beta-1,4-glucanase activity under slightly acid to alkaline conditions and improved performance in paper pulp processing, textile treatment, laundry processes, extraction processes or in animal feed; preferably such novel well-performing endo-glucanases are producible or produced by using recombinant techniques in high yields.

SUMMARY OF THE INVENTION

**[0010]** The present invention relates to isolated polypeptides having endoglucanase activity selected from the group consisting of:

**[0011]** (a) a polypeptide having an amino acid sequence which has at least 72% identity with amino acids 1 to 759 of SEQ ID NO: 2;

**[0012]** (b) a polypeptide which is encoded by a nucleotide sequence which hybridizes under at least low stringency conditions with (i) nucleotides 100 to 2376 of SEQ ID NO: 1, or (ii) a complementary strand of (i); and

**[0013]** (c) a variant comprising a conservative substitution, deletion, and/or insertion of one or more amino acids of amino acids 1 to 759 of SEQ ID NO: 2.

**[0014]** The present invention also relates to isolated polynucleotides encoding polypeptides having endoglucanase activity, selected from the group consisting of:

**[0015]** (a) a polynucleotide encoding a polypeptide having an amino acid sequence which has at least 72% identity with amino acids 1 to 759 of SEQ ID NO: 2;

**[0016]** (b) a polynucleotide which hybridizes under at least low stringency conditions with (i) nucleotides 100 to 2376 of SEQ ID NO: 1, or (ii) a complementary strand of (i).

**[0017]** The present invention also relates to nucleic acid constructs, recombinant expression vectors, and recombinant host cells comprising the polynucleotides.

The present invention also relates to methods for producing such polypeptides having endoglucanase activity comprising (a) cultivating a recombinant host cell comprising a nucleic



acid construct comprising a polynucleotide encoding the polypeptide under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

**[0018]** The endo-beta-1,4-glucanase of the invention has stability and activity properties that make it exceptionally well-suited for use in applications involving aqueous alkaline solutions that contain surfactants and/or oxidative active species such as chemical bleaches. Such application conditions are very commonly found, both within household and industrial detergents, textile finishing treatments and in the manufacture or recycling of cellulosic pulps.

**[0019]** Because the endoglucanase of the invention maintains its activity to an exceptional extent under such relevant application conditions it is contemplated that it will be more useful than other known enzymes, e.g., when used in detergents, for paper/pulp processing or for textile treatments. The present invention thus also relates to methods of using the polypeptides of the invention in a detergent or textile treatment composition, a composition for treatment of paper pulp or for degradation of biomass e.g. for the production of ethanol. Further, the invention relates to methods for washing textile, kitchenware or hard surfaces with a detergent comprising the polypeptides, methods for treatment of cellulosic textile or fabrics, such as softening, bio-polishing or stone-washing. Also, methods for improving the drainage or for de-inking of recycled paper are included.

**[0020]** The present invention further relates to nucleic acid constructs comprising a gene encoding a protein, wherein the gene is operably linked to one or both of a first nucleotide sequence encoding a signal peptide consisting of nucleotides 1 to 99 of SEQ ID NO: 1.

#### BRIEF DESCRIPTION OF THE FIGURES

**[0021]** FIG. 1, Alignment of the amino acid sequence of the polypeptide of the invention (ACE160, SEQ ID NO:2) with related polypeptides of the prior art. The prior art polypeptides are disclosed as:

Name	Entry number	Patent number
KSM-64	ADP87708, GeneseqP	JP2004173598
KSM-365	AAR77395, GeneseqP	JP07203960-1994
KSM-634	AAR07478, GeneseqP	JP01281090
KSM-S237	ADP87707, GeneseqP	JP2004173598
MB1181	ABG76403, GeneseqP	WO200299091
KSM-635	P19424, Uniprot	—

**[0022]** FIG. 2, Phylogenetic tree showing the relationship of the endoglucanase of the invention (ACE160, SEQ ID NO:2) with prior art polypeptide sequences were constructed upon alignment with default settings in the ClustaIV function of program MegAlign™ version 5.05 in DNASTar™ program package.

#### DEFINITIONS

**[0023]** Endoglucanase activity: The term “endoglucanase activity” is defined herein as a hydrolytic activity which catalyzes the endohydrolysis of 1,4-beta-D-glucosidic linkages in cellulose, lichenin and cereal beta-D-glucans, EC 3.2.1.4. A method for determination of endoglucanase activity is described below.

**[0024]** The polypeptides of the present invention have at least 70%, more preferably at least 80%, even more prefer-

ably at least 90%, even more preferably at least 95%, most preferably at least 98%, and even most preferably at least 100% of the endoglucanase activity of the polypeptide consisting of the amino acid sequence shown as amino acids 1 to 759 of SEQ ID NO: 2, or the catalytic core domain consisting of the amino acid 65 to 347 of SEQ ID NO: 2.

**[0025]** Isolated polypeptide: The term “isolated polypeptide” as used herein refers to a polypeptide which is at least 20% pure, preferably at least 40% pure, more preferably at least 60% pure, even more preferably at least 80% pure, most preferably at least 90% pure, and even most preferably at least 95% pure, as determined by SDS-PAGE.

**[0026]** Substantially pure polypeptide: The term “substantially pure polypeptide” denotes herein a polypeptide preparation which contains at most 10%, preferably at most 8%, more preferably at most 6%, more preferably at most 5%, more preferably at most 4%, at most 3%, even more preferably at most 2%, most preferably at most 1%, and even most preferably at most 0.5% by weight of other polypeptide material with which it is natively associated. It is, therefore, preferred that the substantially pure polypeptide is at least 92% pure, preferably at least 94% pure, more preferably at least 95% pure, more preferably at least 96% pure, more preferably at least 97% pure, more preferably at least 98% pure, even more preferably at least 99%, most preferably at least 99.5% pure, and even most preferably 100% pure by weight of the total polypeptide material present in the preparation.

**[0027]** The polypeptides of the present invention are preferably in a substantially pure form. In particular, it is preferred that the polypeptides are in “essentially pure form”, i.e., that the polypeptide preparation is essentially free of other polypeptide material with which it is natively associated. This can be accomplished, for example, by preparing the polypeptide by means of well-known recombinant methods or by classical purification methods.

**[0028]** Herein, the term “substantially pure polypeptide” is synonymous with the terms “isolated polypeptide” and “polypeptide in isolated form.”

**[0029]** Identity: The relatedness between two amino acid sequences is described by the parameter “identity”.

**[0030]** For purposes of the present invention, the alignment of two amino acid sequences is determined by using the Needle program from the EMBOSS package (<http://emboss.org>) version 2.8.0. The Needle program implements the global alignment algorithm described in Needleman, S. B. and Wunsch, C. D. (1970) J. Mol. Biol. 48, 443-453. The substitution matrix used is BLOSUM62, gap opening penalty is 10, and gap extension penalty is 0.5.

**[0031]** The degree of identity between an amino acid sequence of the present invention (“invention sequence”; e.g. amino acids 1 to 759 of SEQ ID NO:2 or the catalytic core domain of amino acids 65 to 347 of SEQ ID NO:2) and a different amino acid sequence (“foreign sequence”) is calculated as the number of exact matches in an alignment of the two sequences, divided by the length of the “invention sequence” or the length of the “foreign sequence”, whichever is the shortest. The result is expressed in percent identity.

**[0032]** An exact match occurs when the “invention sequence” and the “foreign sequence” have identical amino acid residues in the same positions of the overlap (in the alignment example below this is represented by “|”). The length of a sequence is the number of amino acid residues in



the sequence (e.g. the length of the “invention sequence” of SEQ ID NO:2 is 759 amino acids).

[0033] In the alignment example below, the overlap is the amino acid sequence “HTWGER.NLG” of Sequence 1; or the amino acid sequence “HGWGEDANLA” of Sequence 2. A gap is indicated by a “.”.

#### ALIGNMENT EXAMPLE

[0034]

```
Sequence 1:  ACMSHTWGER.NLG
              | | | | |
Sequence 2:   HGWGEDANLAMNPS
```

[0035] The length of the overlap of the “invention sequence” may be at least 20% of the length of the “invention sequence”, more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, or at least 90% of the length of the “invention sequence”.

[0036] The length of the overlap of the “foreign sequence” may be at least 20% of the length of the “foreign sequence”, more preferably at least 30%, 40%, 50%, 60%, 70%, 80%, or at least 90% of the length of the “invention sequence”.

[0037] Polypeptide Fragment: The term “polypeptide fragment” is defined herein as a polypeptide having one or more amino acids deleted from the amino and/or carboxyl terminus of SEQ ID NO: 2 or a homologous sequence thereof, wherein the fragment has endoglucanase activity. Preferably, the fragment contains at least 283 amino acid residues, e.g., amino acids 65 to 347 of SEQ ID NO: 2.

[0038] Subsequence: The term “subsequence” is defined herein as a nucleotide sequence having one or more nucleotides deleted from the 5' and/or 3' end of SEQ ID NO: 1 or a homologous sequence thereof, wherein the subsequence encodes a polypeptide fragment having endoglucanase activity. Preferably, a subsequence contains at least 849 nucleotides, e.g., nucleic acids 193 to 1041 of SEQ ID NO:1.

[0039] Allelic variant: The term “allelic variant” denotes herein any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

[0040] Substantially pure polynucleotide: The term “substantially pure polynucleotide” as used herein refers to a polynucleotide preparation free of other extraneous or unwanted nucleotides and in a form suitable for use within genetically engineered protein production systems. Thus, a substantially pure polynucleotide contains at most 10%, preferably at most 8%, more preferably at most 6%, more preferably at most 5%, more preferably at most 4%, more preferably at most 3%, even more preferably at most 2%, most preferably at most 1%, and even most preferably at most 0.5% by weight of other polynucleotide material with which it is natively associated. A substantially pure polynucleotide may, however, include naturally occurring 5' and 3' untranslated regions, such as promoters and terminators. It is preferred that the substantially pure polynucleotide is at least 90% pure, preferably at least 92% pure, more preferably at least 94% pure, more preferably at least 95% pure, more preferably at

least 96% pure, more preferably at least 97% pure, even more preferably at least 98% pure, most preferably at least 99%, and even most preferably at least 99.5% pure by weight. The polynucleotides of the present invention are preferably in a substantially pure form. In particular, it is preferred that the polynucleotides disclosed herein are in “essentially pure form”, i.e., that the polynucleotide preparation is essentially free of other polynucleotide material with which it is natively associated. Herein, the term “substantially pure polynucleotide” is synonymous with the terms “isolated polynucleotide” and “polynucleotide in isolated form.” The polynucleotides may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.

[0041] Nucleic acid construct: The term “nucleic acid construct” as used herein refers to a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term “expression cassette” when the nucleic acid construct contains the control sequences required for expression of a coding sequence of the present invention.

[0042] Control sequence: The term “control sequences” is defined herein to include all components, which are necessary or advantageous for the expression of a polynucleotide encoding a polypeptide of the present invention. Each control sequence may be native or foreign to the nucleotide sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleotide sequence encoding a polypeptide.

[0043] Operably linked: The term “operably linked” denotes herein a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of the polynucleotide sequence such that the control sequence directs the expression of the coding sequence of a polypeptide.

[0044] Coding sequence: When used herein the term “coding sequence” means a nucleotide sequence, which directly specifies the amino acid sequence of its protein product. The boundaries of the coding sequence are generally determined by an open reading frame, which usually begins with the ATG start codon or alternative start codons such as GTG and TTG. The coding sequence may be a DNA, cDNA, or recombinant nucleotide sequence.

[0045] Expression: The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0046] Expression vector: The term “expression vector” is defined herein as a linear or circular DNA molecule that comprises a polynucleotide encoding a polypeptide of the invention, and which is operably linked to additional nucleotides that provide for its expression.

[0047] Host cell: The term “host cell”, as used herein, includes any cell type which is susceptible to transformation,



transfection, transduction, and the like with a nucleic acid construct comprising a polynucleotide of the present invention.

#### DETAILED DESCRIPTION OF THE INVENTION

##### Polypeptides Having Endoglucanase Activity

**[0048]** In a first aspect, the present invention relates to isolated polypeptides having an amino acid sequence which has a degree of identity to amino acids 1 to 759 of SEQ ID NO:2, i.e., the mature polypeptide of at least 72%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, most preferably at least 95%, and even most preferably at least 97%, which have endoglucanase activity (hereinafter “homologous polypeptides”). In a preferred aspect, the homologous polypeptides have an amino acid sequence which differs by ten amino acids, preferably by five amino acids, more preferably by four amino acids, even more preferably by three amino acids, most preferably by two amino acids, and even most preferably by one amino acid from amino acids 1 to 759 of SEQ ID NO:2.

**[0049]** A polypeptide of the present invention preferably comprises the amino acid sequence of SEQ ID NO:2 or an allelic variant thereof; or a fragment thereof that has endoglucanase activity. In a preferred aspect, a polypeptide comprises the amino acid sequence of SEQ ID NO:2. In another preferred aspect, a polypeptide consists of the amino acid sequence of SEQ ID NO:2 or an allelic variant thereof; or a fragment thereof that has endoglucanase activity. In another preferred aspect, a polypeptide consists of the amino acid sequence of SEQ ID NO:2.

**[0050]** In another preferred aspect, a polypeptide comprises a catalytic core domain in amino acids 65 to 347 of SEQ ID NO:2, or an allelic variant thereof; or a fragment thereof that has endoglucanase activity. The polypeptide of the catalytic core domain has an amino acid sequence which has a degree of identity to amino acids 65 to 347 of SEQ ID NO:2 of at least 86%, more preferably at least 88%, even more preferably at least 90%, most preferably at least 95%, and even most preferably at least 97%. In another preferred aspect, a polypeptide comprises a catalytic core domain in amino acids 65 to 347 of SEQ ID NO:2, or an allelic variant thereof; or a fragment thereof that has endoglucanase activity. In another preferred aspect, a polypeptide consists of amino acids 65 to 347 of SEQ ID NO:2.

**[0051]** The annotation of the catalytic core domain is based on homology to cellulases of the Glycosyl hydrolase Family 5 (Henrissat B. A classification of glycosyl hydrolases based on amino acid sequence similarities. *Biochem. J.* 280 309-316 (1991); Henrissat B., Bairoch A. New families in the classification of glycosyl hydrolases based on amino acid sequence similarities. *Biochem. J.* 293 781-788 (1993); Henrissat B., Bairoch A. Updating the sequence-based classification of glycosyl hydrolases. *Biochem. J.* 316 695-696 (1996); Davies G., Henrissat B. Structures and mechanisms of glycosyl hydrolases. *Structure* 3 853-859 (1995); Henrissat B., Claeysens M., Tomme P., Lemesle L., Mornon J.-P. Cellulase families revealed by hydrophobic cluster analysis. *Gene* 81 83-95 (1989); Py B., Bortoli-German I., Haiech J., Chippaux M., Barras F. Cellulase EGZ of *Erwinia chrysanthemi*: structural organization and importance of His98 and Glu133 residues for catalysis. *Protein Eng.* 4 325-333 (1991)). The domain annotation of the catalytic core domain is available

through <http://afmb.cnrs-mrs.fr/CAZY/>, <http://www.ebi.ac.uk/interpro/>, <http://www.sanger.ac.uk/Software/Pfam/>, or <http://www.expasy.org/prosite/>.

**[0052]** In another aspect of the invention, the polypeptide comprises a carbohydrate binding module in amino acids 368 to 569 of SEQ ID NO:2. In another preferred aspect the present invention relates to polypeptides comprising a carbohydrate binding module having a degree of identity to amino acids 368 to 569 of SEQ ID NO:2 of at least 67%, more preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, even more preferably at least 90%, most preferably at least 95%, and even most preferably at least 97%. In another preferred aspect, a polypeptide comprises a carbohydrate binding module in amino acids 368 to 569 of SEQ ID NO:2, or an allelic variant thereof; or a fragment thereof that has carbohydrate binding activity. In another preferred aspect, a polypeptide consists of amino acids 368 to 569 of SEQ ID NO:2.

**[0053]** The carbohydrate binding module belongs to the family 17/28. The annotation of the CBM is based on homology with known sequences, especially the CBM of KSM-635 (Ozaki, K. Shikata, S. Kawai, S. Ito, S. Okamoto, K.; “Molecular cloning and nucleotide sequence of a gene for alkaline cellulase from *Bacillus* sp. KSM-635.”; *J. Gen. Microbiol.* 136:1327-1334 (1990), Uniprot No. P19424), which was annotated as a CBM based on relation to the galactose binding like domains described in Ito N., Phillips S. E., Stevens C., Ogel Z. B., McPherson M. J., Keen J. N., Yadav K. D., Knowles P. F. Novel thioether bond revealed by a 1.7 Å crystal structure of galactose oxidase. *Nature* 350 87-90 (1991); Macedo-ribeiro S., Bode W., Huber R., Quinn-Allen M. A., Kim S. W., Ortel T. L., Bourenkov G. P., Bartunik H. D., Stubbs M. T., Kane W. H., Fuentes-prior P. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. *Nature* 402 434-439 (1999); Himanen J. P., Rajashankar K. R., Lackmann M., Cowan C. A., Henkemeyer M., Nikolov D. B. Crystal structure of an Eph receptor-ephrin complex. *Nature* 414 933-938 (2001) [PUBMED:11780069] [PUB00010665]; and Marintchev A., Mullen M. A., Maciejewski M. W., Pan B., Gryk M. R., Mullen G. P. Solution structure of the single-strand break repair protein XRCC1 N-terminal domain. *Nat. Struct. Biol.* 6 884-893 (1999). The domain annotation of the carbohydrate binding module is available through <http://afmb.cnrs-mrs.fr/CAZY/>, <http://www.ebi.ac.uk/interpro/>, <http://www.sanger.ac.uk/Software/Pfam/>, or <http://www.expasy.org/prosite/>.

**[0054]** In a second aspect, the present invention relates to isolated polypeptides having endoglucanase activity which are encoded by polynucleotides which hybridize under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with (i) nucleotides 100 to 2376 of SEQ ID NO: 1, (ii) a subsequence of (i) or (iii) a complementary strand of (i) or (ii) (J. Sambrook, E. F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning, A Laboratory Manual*, 2d edition, Cold Spring Harbor, N.Y.). A subsequence of SEQ ID NO: 1 contains at least 100 contiguous nucleotides or preferably at least 200 contiguous nucleotides, more preferably 300, 400, 500, 600, 700, 800, 900 contiguous nucleotides or even more preferably at least 1000 contiguous nucleotides. Moreover, the subsequence may encode a polypeptide fragment which has endoglucanase activity.



**[0055]** The nucleotide sequence of SEQ ID NO: 1 or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, may be used to design a nucleic acid probe to identify and clone DNA encoding polypeptides having endoglucanase activity from strains of different genera or species according to methods well known in the art. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 14, preferably at least 25, more preferably at least 35, and most preferably at least 70 nucleotides in length. It is, however, preferred that the nucleic acid probe is at least 100 nucleotides in length. For example, the nucleic acid probe may be at least 200 nucleotides, preferably at least 300 nucleotides, more preferably at least 400 nucleotides, or most preferably at least 500 nucleotides in length. Even longer probes may be used, e.g., nucleic acid probes which are at least 600 nucleotides, at least preferably at least 700 nucleotides, more preferably at least 800 nucleotides, or most preferably at least 900 nucleotides in length. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{35}\text{S}$ , biotin, or avidin). Such probes are encompassed by the present invention.

**[0056]** A genomic DNA library prepared from such other organisms may, therefore, be screened for DNA which hybridizes with the probes described above and which encodes a polypeptide having endoglucanase activity. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify a clone or DNA which is homologous with SEQ ID NO:1 or a subsequence thereof, the carrier material is used in a Southern blot.

**[0057]** For purposes of the present invention, hybridization indicates that the nucleotide sequence hybridizes to a labeled nucleic acid probe corresponding to the nucleotide sequence shown in SEQ ID NO:1, its complementary strand, or a subsequence thereof, under very low to very high stringency conditions. Molecules to which the nucleic acid probe hybridizes under these conditions can be detected using X-ray film.

**[0058]** In a preferred aspect, the nucleic acid probe is nucleotides 193 to 1041 of SEQ ID NO:1. In another preferred aspect, the nucleic acid probe is a polynucleotide sequence which encodes the polypeptide of SEQ ID NO:2, or a subsequence thereof. In another preferred aspect, the nucleic acid probe is SEQ ID NO:1. In another preferred aspect, the nucleic acid probe is the mature polypeptide coding region of SEQ ID NO:1.

**[0059]** For long probes of at least 100 nucleotides in length, very low to very high stringency conditions are defined as prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 µg/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures for 12 to 24 hours optimally.

**[0060]** For long probes of at least 100 nucleotides in length, the carrier material is finally washed three times each for 15

minutes using 2×SSC, 0.2% SDS preferably at least at 45° C. (very low stringency), more preferably at least at 50° C. (low stringency), more preferably at least at 55° C. (medium stringency), more preferably at least at 60° C. (medium-high stringency), even more preferably at least at 65° C. (high stringency), and most preferably at least at 70° C. (very high stringency). Preferably, the wash is conducted using 0.2×SSC, 0.2% SDS preferably at least at 45° C. (very low stringency), more preferably at least at 50° C. (low stringency), more preferably at least at 55° C. (medium stringency), more preferably at least at 60° C. (medium-high stringency), even more preferably at least at 65° C. (high stringency), and most preferably at least at 70° C. (very high stringency).

**[0061]** For short probes which are about 15 nucleotides to about 70 nucleotides in length, stringency conditions are defined as prehybridization, hybridization, and washing post-hybridization at about 5° C. to about 10° C. below the calculated  $T_m$  using the calculation according to Bolton and McCarthy (1962, *Proceedings of the National Academy of Sciences USA* 48:1390) in 0.9 M NaCl, 0.09 M Tris-HCl pH 7.6, 6 mM EDTA, 0.5% NP-40, 1× Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures.

**[0062]** For short probes which are about 15 nucleotides to about 70 nucleotides in length, the carrier material is washed once in 6×SSC plus 0.1% SDS for 15 minutes and twice each for 15 minutes using 6×SSC at 5° C. to 10° C. below the calculated  $T_m$ .

**[0063]** In a third aspect, the present invention relates to isolated polypeptides having endoglucanase activity encoded by a polynucleotide comprising nucleotides 193 to 1041 of SEQ ID NO: 1, as a unique motif.

**[0064]** In a fourth aspect, the present invention relates to isolated polypeptides having the following physicochemical properties: pI of 4.4, pH optimum of 9, temperature optimum of 40° C. and stability at pH from 5 to 10.5. The beta-1,4-glucanase of the invention is not significantly inactivated by Fe(II) ions. A sensitivity of the enzymatic activity of the polypeptide to the presence of ferrous ions could place restrictions on the applicability of the polypeptide, such as in processes taking place in metal containers or equipment.

**[0065]** In a fifth aspect, the present invention relates to artificial variants comprising a conservative substitution, deletion, and/or insertion of one or more amino acids of SEQ ID NO: 2 or the mature polypeptide thereof. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.

**[0066]** Examples of conservative substitutions are within the group of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter specific activity are known in the art and are described, for



example, by H. Neurath and R. L. Hill, 1979, *In, The Proteins*, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly.

[0067] In addition to the 20 standard amino acids, non-standard amino acids (such as 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid, isovaline, and alpha-methyl serine) may be substituted for amino acid residues of a wild-type polypeptide. A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, and unnatural amino acids may be substituted for amino acid residues. "Unnatural amino acids" have been modified after protein synthesis, and/or have a chemical structure in their side chain(s) different from that of the standard amino acids. Unnatural amino acids can be chemically synthesized, and preferably, are commercially available, and include pipercolic acid, thiazolidine carboxylic acid, dehydroproline, 3- and 4-methylproline, and 3,3-dimethylproline.

[0068] Alternatively, the amino acid changes are of such a nature that the physico-chemical properties of the polypeptides are altered. For example, amino acid changes may improve the thermal stability of the polypeptide, alter the substrate specificity, change the pH optimum, and the like.

[0069] Essential amino acids in the parent polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity (i.e., endoglucanase activity) to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et al., 1996, *J. Biol. Chem.* 271: 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., 1992, *Science* 255: 306-312; Smith et al., 1992, *J. Mol. Biol.* 224: 899-904; Wlodaver et al., 1992, *FEBS Lett.* 309:59-64. The identities of essential amino acids can also be inferred from analysis of identities with polypeptides which are related to a polypeptide according to the invention.

[0070] Single or multiple amino acid substitutions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, *Science* 241: 53-57; Bowie and Sauer, 1989, *Proc. Natl. Acad. Sci. USA* 86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et al., 1991, *Biochem.* 30:10832-10837; U.S. Pat. No. 5,223,409; WO 92/06204), and region-directed mutagenesis (Derbyshire et al., 1986, *Gene* 46:145; Ner et al., 1988, *DNA* 7:127).

#### Sources of Polypeptides Having Endoglucanase Activity

[0071] A polypeptide of the present invention may be obtained from microorganisms of any genus. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the polypeptide encoded by a nucleotide sequence is produced by the source or by a strain in which the nucleotide sequence

from the source has been inserted. In a preferred aspect, the polypeptide obtained from a given source is secreted extracellularly.

[0072] A polypeptide of the present invention may be a bacterial polypeptide. For example, the polypeptide may be a gram positive bacterial polypeptide such as a *Bacillus* polypeptide, e.g., a *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, or *Bacillus thuringiensis* polypeptide; or a *Streptomyces* polypeptide, e.g., a *Streptomyces lividans* or *Streptomyces murinus* polypeptide; or a gram negative bacterial polypeptide, e.g., an *E. coli* or a *Pseudomonas* sp. polypeptide.

[0073] In another preferred aspect, the polypeptide is a *Bacillus* sp. ACE160 polypeptide e.g., the polypeptide of SEQ ID NO:2.

[0074] It will be understood that for the aforementioned species, the invention encompasses both the perfect and imperfect states, and other taxonomic equivalents, e.g., anamorphs, regardless of the species name by which they are known. Those skilled in the art will readily recognize the identity of appropriate equivalents.

[0075] Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).

[0076] Furthermore, such polypeptides may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The polynucleotide may then be obtained by similarly screening a genomic or cDNA library of another microorganism. Once a polynucleotide sequence encoding a polypeptide has been detected with the probe(s), the polynucleotide can be isolated or cloned by utilizing techniques which are well known to those of ordinary skill in the art (see, e.g., Sambrook et al., 1989, *supra*).

[0077] Polypeptides of the present invention also include fused polypeptides or cleavable fusion polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleotide sequence (or a portion thereof) encoding another polypeptide to a nucleotide sequence (or a portion thereof) of the present invention. Techniques for producing fusion polypeptides are known in the art, and include ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter (s) and terminator.

#### Polynucleotides

[0078] The present invention also relates to isolated polynucleotides having a nucleotide sequence which encode a polypeptide of the present invention. In a preferred aspect, the nucleotide sequence is set forth in SEQ ID NO:1. In another preferred aspect, the nucleotide sequence is the mature polypeptide coding region of SEQ ID NO:1. The present invention also encompasses nucleotide sequences which



encode a polypeptide having the amino acid sequence of SEQ ID NO:2 or the mature polypeptide thereof, which differs from SEQ ID NO:1 by virtue of the degeneracy of the genetic code. The present invention also relates to subsequences of SEQ ID NO:1 which encode fragments of SEQ ID NO:2 that have endoglucanase activity, such as the catalytic core domain of amino acid 65 to 347 of SEQ ID NO:2 or the fragment of amino acid 368 to 569 of SEQ ID NO:2.

**[0079]** The present invention also relates to mutant polynucleotides comprising at least one mutation in the mature polypeptide coding sequence of SEQ ID NO:1, in which the mutant nucleotide sequence encodes a polypeptide which consists of amino acids 1 to 759 of SEQ ID NO:2.

**[0080]** The techniques used to isolate or clone a polynucleotide encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the polynucleotides of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR) or antibody screening of expression libraries to detect cloned DNA fragments with shared structural features. See, e.g., Innis et al., 1990, *PCR: A Guide to Methods and Application*, Academic Press, New York. Other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleotide sequence-based amplification (NASBA) may be used. The polynucleotides may be cloned from a strain of *Bacillus*, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleotide sequence.

**[0081]** The present invention also relates to polynucleotides having nucleotide sequences which have a degree of identity to the mature polypeptide coding sequence of SEQ ID NO:1 (i.e., nucleotides 100 to 2376) of at least 60%, preferably at least 65%, more preferably at least 70%, more preferably at least 75%, more preferably at least 80%, more preferably at least 85%, more preferably at least 90%, even more preferably at least 95%, and most preferably at least 97% identity, which encode an active polypeptide.

**[0082]** Modification of a nucleotide sequence encoding a polypeptide of the present invention may be necessary for the synthesis of polypeptides substantially similar to the polypeptide. The term "substantially similar" to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source, e.g., artificial variants that differ in specific activity, thermostability, pH optimum, or the like. The variant sequence may be constructed on the basis of the nucleotide sequence presented as the polypeptide encoding region of SEQ ID NO:1, e.g., a subsequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleotide sequence, but which correspond to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, e.g., Ford et al., 1991, *Protein Expression and Purification 2*: 95-107.

**[0083]** It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by an isolated polynucleotide of the

invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, *Science* 244: 1081-1085). In the latter technique, mutations are introduced at every positively charged residue in the molecule, and the resultant mutant molecules are tested for endoglucanase activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of the three-dimensional structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., deVos et al., 1992, *Science* 255: 306-312; Smith et al., 1992, *Journal of Molecular Biology* 224: 899-904; Wlodaver et al., 1992, *FEBS Letters* 309: 59-64).

**[0084]** The present invention also relates to isolated polynucleotides encoding a polypeptide of the present invention, which hybridize under very low stringency conditions, preferably low stringency conditions, more preferably medium stringency conditions, more preferably medium-high stringency conditions, even more preferably high stringency conditions, and most preferably very high stringency conditions with (i) nucleotides 100 to 2376 of SEQ ID NO:1, (ii) nucleotides 193 to 1041 of SEQ ID NO:1, (iii) nucleotides 1104 to 1707 of SEQ ID NO:1 or (iv) a complementary strand of (i) to (iii); or allelic variants and subsequences thereof (Sambrook et al., 1989, *supra*), as defined herein.

**[0085]** The present invention also relates to isolated polynucleotides obtained by (a) hybridizing a population of DNA under very low, low, medium, medium-high, high, or very high stringency conditions with (i) nucleotides 100 to 2376 of SEQ ID NO:1, or (ii) a complementary strand of (i); and (b) isolating the hybridizing polynucleotide, which encodes a polypeptide having endoglucanase activity.

#### Nucleic Acid Constructs

**[0086]** The present invention also relates to nucleic acid constructs comprising an isolated polynucleotide of the present invention operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.

**[0087]** An isolated polynucleotide encoding a polypeptide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the polynucleotide's sequence prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotide sequences utilizing recombinant DNA methods are well known in the art.

**[0088]** The control sequence may be an appropriate promoter sequence, a nucleotide sequence which is recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the present invention. The promoter sequence contains transcriptional control sequences which mediate the expression of the polypeptide. The promoter may be any nucleotide sequence which shows transcriptional activity in the host cell of choice including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

**[0089]** Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters



obtained from the *E. coli* lac operon, *Streptomyces coelicolor* agarase gene (dagA), *Bacillus subtilis* levansucrase gene (sacB), *Bacillus licheniformis* alpha-amylase gene (amyL), *Bacillus stearothermophilus* maltogenic amylase gene (amyM), *Bacillus amyloliquefaciens* alpha-amylase gene (amyQ), *Bacillus licheniformis* penicillinase gene (penP), *Bacillus subtilis* xylA and xylB genes, and prokaryotic beta-lactamase gene (VIIIa-Kamaroff et al., 1978, *Proceedings of the National Academy of Sciences USA* 75: 3727-3731), as well as the tac promoter (DeBoer et al., 1983, *Proceedings of the National Academy of Sciences USA* 80: 21-25). Further promoters are described in "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242: 74-94; and in Sambrook et al., 1989, supra.

[0090] Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *Aspergillus niger* neutral alpha-amylase, *Aspergillus niger* acid stable alpha-amylase, *Aspergillus niger* or *Aspergillus awamori* glucoamylase (glaA), *Rhizomucor miehei* lipase, *Aspergillus oryzae* alkaline protease, *Aspergillus oryzae* triose phosphate isomerase, *Aspergillus nidulans* acetamidase, *Fusarium venenatum* amyloglucosidase (WO 00/56900), *Fusarium venenatum* Daria (WO 00/56900), *Fusarium venenatum* Quinn (WO 00/56900), *Fusarium oxysporum* trypsin-like protease (WO 96/00787), *Trichoderma reesei* beta-glucosidase, *Trichoderma reesei* cellobiohydrolase I, *Trichoderma reesei* endoglucanase I, *Trichoderma reesei* endoglucanase II, *Trichoderma reesei* endoglucanase III, *Trichoderma reesei* endoglucanase IV, *Trichoderma reesei* endoglucanase V, *Trichoderma reesei* xylanase I, *Trichoderma reesei* xylanase II, *Trichoderma reesei* beta-xylosidase, as well as the NA2-tpi promoter (a hybrid of the promoters from the genes for *Aspergillus niger* neutral alpha-amylase and *Aspergillus oryzae* triose phosphate isomerase); and mutant, truncated, and hybrid promoters thereof.

[0091] In a yeast host, useful promoters are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* galactokinase (GAL1), *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH1, ADH2/GAP), *Saccharomyces cerevisiae* triose phosphate isomerase (TPI), *Saccharomyces cerevisiae* metallothioneine (CUP1), and *Saccharomyces cerevisiae* 3-phosphoglycerate kinase. Other useful promoters for yeast host cells are described by Romanos et al., 1992, *Yeast* 8: 423-488.

[0092] The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3' terminus of the nucleotide sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.

[0093] Preferred terminators for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Aspergillus niger* alpha-glucosidase, and *Fusarium oxysporum* trypsin-like protease.

[0094] Preferred terminators for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase, *Saccharomyces cerevisiae* cytochrome C (CYC1), and *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate

dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra.

[0095] The control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5' terminus of the nucleotide sequence encoding the polypeptide. Any leader sequence that is functional in the host cell of choice may be used in the present invention.

[0096] Preferred leaders for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase and *Aspergillus nidulans* triose phosphate isomerase.

[0097] Suitable leaders for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* enolase (ENO-1), *Saccharomyces cerevisiae* 3-phosphoglycerate kinase, *Saccharomyces cerevisiae* alpha-factor, and *Saccharomyces cerevisiae* alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).

[0098] The control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3' terminus of the nucleotide sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.

[0099] Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* glucoamylase, *Aspergillus nidulans* anthranilate synthase, *Fusarium oxysporum* trypsin-like protease, and *Aspergillus niger* alpha-glucosidase.

[0100] Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, *Molecular Cellular Biology* 15: 5983-5990.

[0101] The control sequence may also be a signal peptide coding region that codes for an amino acid sequence linked to the amino terminus of a polypeptide and directs the encoded polypeptide into the cell's secretory pathway. The 5' end of the coding sequence of the nucleotide sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5' end of the coding sequence may contain a signal peptide coding region which is foreign to the coding sequence. The foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the polypeptide. However, any signal peptide coding region which directs the expressed polypeptide into the secretory pathway of a host cell of choice may be used in the present invention.

[0102] Effective signal peptide coding regions for bacterial host cells are the signal peptide coding regions obtained from the genes for *Bacillus* NCIB 11837 maltogenic amylase, *Bacillus stearothermophilus* alpha-amylase, *Bacillus licheniformis* subtilisin, *Bacillus licheniformis* beta-lactamase, *Bacillus stearothermophilus* neutral proteases (nprT, nprS, nprM), and *Bacillus subtilis* prsA. Further signal peptides are described by Simonen and Palva, 1993, *Microbiological Reviews* 57: 109-137.

[0103] Effective signal peptide coding regions for filamentous fungal host cells are the signal peptide coding regions



obtained from the genes for *Aspergillus oryzae* TAKA amylase, *Aspergillus niger* neutral amylase, *Aspergillus niger* glucoamylase, *Rhizomucor miehei* aspartic proteinase, *Humicola insolens* cellulase, and *Humicola lanuginosa* lipase.

[0104] In a preferred aspect, the signal peptide coding region is nucleotides 1 to 99 of SEQ ID NO:1 which encode amino acids -33 to -1 of SEQ ID NO:2.

[0105] Useful signal peptides for yeast host cells are obtained from the genes for *Saccharomyces cerevisiae* alpha-factor and *Saccharomyces cerevisiae* invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.

[0106] The control sequence may also be a propeptide coding region that codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the genes for *Bacillus subtilis* alkaline protease (aprE), *Bacillus subtilis* neutral protease (nprT), *Saccharomyces cerevisiae* alpha-factor, *Rhizomucor miehei* aspartic proteinase, and *Myceliophthora thermophila* laccase (WO 95/33836).

[0107] Where both signal peptide and propeptide regions are present at the amino terminus of a polypeptide, the propeptide region is positioned next to the amino terminus of a polypeptide and the signal peptide region is positioned next to the amino terminus of the propeptide region.

[0108] It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GALL system may be used. In filamentous fungi, the TAKA alpha-amylase promoter, *Aspergillus niger* glucoamylase promoter, and *Aspergillus oryzae* glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleotide sequence encoding the polypeptide would be operably linked with the regulatory sequence.

#### Expression Vectors

[0109] The present invention also relates to recombinant expression vectors comprising a polynucleotide of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acids and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleotide sequence encoding the polypeptide at such sites. Alternatively, a nucleotide sequence of the present invention may be expressed by inserting the nucleotide sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In

creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.

[0110] The recombinant expression vector may be any vector (e.g., a plasmid or virus) which can be conveniently subjected to recombinant DNA procedures and can bring about expression of the nucleotide sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids.

[0111] The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

[0112] The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

[0113] A conditionally essential gene may function as a non-antibiotic selectable marker. Non-limiting examples of bacterial conditionally essential non-antibiotic selectable markers are the dal genes from *Bacillus subtilis*, *Bacillus licheniformis*, or other *Bacilli*, that are only essential when the bacterium is cultivated in the absence of D-alanine. Also the genes encoding enzymes involved in the turnover of UDP-galactose can function as conditionally essential markers in a cell when the cell is grown in the presence of galactose or grown in a medium which gives rise to the presence of galactose. Non-limiting examples of such genes are those from *B. subtilis* or *B. licheniformis* encoding UTP-dependent phosphorylase (EC 2.7.7.10), UDP-glucose-dependent uridylyltransferase (EC 2.7.7.12), or UDP-galactose epimerase (EC 5.1.3.2). Also a xylose isomerase gene such as xylA, of *Bacilli* can be used as selectable markers in cells grown in minimal medium with xylose as sole carbon source. The genes necessary for utilizing gluconate, gntK, and gntP can also be used as selectable markers in cells grown in minimal medium with gluconate as sole carbon source. Other examples of conditionally essential genes are known in the art. Antibiotic selectable markers confer antibiotic resistance to such antibiotics as ampicillin, kanamycin, chloramphenicol, erythromycin, tetracycline, neomycin, hygromycin or methotrexate.

[0114] Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in a filamentous fungal host cell include, but are not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenylyltransferase), and trpC (anthranilate synthase), as well as equivalents thereof. Preferred for use in an



*Aspergillus* cell are the *amdS* and *pyrG* genes of *Aspergillus nidulans* or *Aspergillus oryzae* and the *bar* gene of *Streptomyces hygrosopicus*.

[0115] The vectors of the present invention preferably contain an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.

[0116] For integration into the host cell genome, the vector may rely on the polynucleotide's sequence encoding the polypeptide or any other element of the vector for integration into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleotide sequences for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, preferably 400 to 10,000 base pairs, and most preferably 800 to 10,000 base pairs, which have a high degree of identity with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleotide sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

[0117] For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. The origin of replication may be any plasmid replicator mediating autonomous replication which functions in a cell. The term "origin of replication" or "plasmid replicator" is defined herein as a nucleotide sequence that enables a plasmid or vector to replicate in vivo.

[0118] Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in *E. coli*, and pUB110, pE194, pTA1060, and pAMf1 permitting replication in *Bacillus*.

[0119] Examples of origins of replication for use in a yeast host cell are the 2 micron origin of replication, ARS1, ARS4, the combination of ARS1 and CEN3, and the combination of ARS4 and CEN6.

[0120] Examples of origins of replication useful in a filamentous fungal cell are AMA1 and ANS1 (Gems et al., 1991, *Gene* 98:61-67; Cullen et al., 1987, *Nucleic Acids Research* 15: 9163-9175; WO 00/24883). Isolation of the AMA1 gene and construction of plasmids or vectors comprising the gene can be accomplished according to the methods disclosed in WO 00/24883.

[0121] More than one copy of a polynucleotide of the present invention may be inserted into the host cell to increase production of the gene product. An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the polynucleotide where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.

[0122] The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, *supra*).

#### Host Cells

[0123] The present invention also relates to recombinant host cells, comprising a polynucleotide of the present invention, which are advantageously used in the recombinant production of the polypeptides. A vector comprising a polynucleotide of the present invention is introduced into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.

[0124] The host cell may be a unicellular microorganism, e.g., a prokaryote, or a non-unicellular microorganism, e.g., a eukaryote.

[0125] Useful unicellular microorganisms are bacterial cells such as gram positive bacteria including, but not limited to, a *Bacillus* cell, e.g., *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus brevis*, *Bacillus circulans*, *Bacillus clausii*, *Bacillus coagulans*, *Bacillus lautus*, *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus stearothermophilus*, *Bacillus subtilis*, and *Bacillus thuringiensis*; or a *Streptomyces* cell, e.g., *Streptomyces lividans* and *Streptomyces murinus*, or gram negative bacteria such as *E. coli* and *Pseudomonas* sp. In a preferred aspect, the bacterial host cell is a *Bacillus lentus*, *Bacillus licheniformis*, *Bacillus stearothermophilus*, or *Bacillus subtilis* cell. In another preferred aspect, the *Bacillus* cell is an alkalophilic *Bacillus*.

[0126] The introduction of a vector into a bacterial host cell may, for instance, be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, *Molecular General Genetics* 168: 111-115), using competent cells (see, e.g., Young and Spizizin, 1961, *Journal of Bacteriology* 81: 823-829, or Dubnau and Davidoff-Abelson, 1971, *Journal of Molecular Biology* 56: 209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, *Biotechniques* 6: 742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, *Journal of Bacteriology* 169: 5771-5278).

[0127] The host cell may also be a eukaryote, such as a mammalian, insect, plant, or fungal cell.

[0128] In a preferred aspect, the host cell is a fungal cell. "Fungi" as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., *In, Ainsworth and Bisby's Dictionary of The Fungi*, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, *supra*, page 171) and all mitosporic fungi (Hawksworth et al., 1995, *supra*).

[0129] In a more preferred aspect, the fungal host cell is a yeast cell. "Yeast" as used herein includes ascosporegenous yeast (Endomycetales), basidiosporegenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in *Biology and Activities of Yeast* (Skinner, F. A., Passmore, S. M., and Davenport, R. R., eds, *Soc. App. Bacteriol. Symposium Series* No. 9, 1980).



[0130] In an even more preferred aspect, the yeast host cell is a *Candida*, *Hansenula*, *Kluyveromyces*, *Pichia*, *Saccharomyces*, *Schizosaccharomyces*, or *Yarrowia* cell.

[0131] In a most preferred aspect, the yeast host cell is a *Saccharomyces carlsbergensis*, *Saccharomyces cerevisiae*, *Saccharomyces diastaticus*, *Saccharomyces douglasii*, *Saccharomyces kluyveri*, *Saccharomyces norbensis* or *Saccharomyces oviformis* cell. In another most preferred aspect, the yeast host cell is a *Kluyveromyces lactis* cell. In another most preferred aspect, the yeast host cell is a *Yarrowia lipolytica* cell.

[0132] In another more preferred aspect, the fungal host cell is a filamentous fungal cell. "Filamentous fungi" include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as *Saccharomyces cerevisiae* is by budding of a unicellular thallus and carbon catabolism may be fermentative.

[0133] In an even more preferred aspect, the filamentous fungal host cell is an *Acremonium*, *Aspergillus*, *Aureobasidium*, *Bjerkandera*, *Ceriporiopsis*, *Coprinus*, *Coriolus*, *Cryptococcus*, *Filobasidium*, *Fusarium*, *Humicola*, *Magnaporthe*, *Mucor*, *Myceliophthora*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Phanerochaete*, *Phlebia*, *Piromyces*, *Pleurotus*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, *Trametes*, or *Trichoderma* cell.

[0134] In a most preferred aspect, the filamentous fungal host cell is an *Aspergillus awamori*, *Aspergillus fumigatus*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger* or *Aspergillus oryzae* cell. In another most preferred aspect, the filamentous fungal host cell is a *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium gramineum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcocroum*, *Fusarium sporotrichioides*, *Fusarium sulphureum*, *Fusarium torulosum*, *Fusarium trichothecioides*, or *Fusarium venenatum* cell. In another most preferred aspect, the filamentous fungal host cell is a *Bjerkandera adusta*, *Ceriporiopsis aneirina*, *Ceriporiopsis aneirina*, *Ceriporiopsis caregiea*, *Ceriporiopsis gilvescens*, *Ceriporiopsis pannocinta*, *Ceriporiopsis rivulosa*, *Ceriporiopsis subrufa*, or *Ceriporiopsis subvermisporea*, *Coprinus cinereus*, *Coriolus hirsutus*, *Humicola insolens*, *Humicola lanuginosa*, *Mucor miehei*, *Myceliophthora thermophila*, *Neurospora crassa*, *Penicillium purpurogenum*, *Phanerochaete chrysosporium*, *Phlebia radiata*, *Pleurotus eryngii*, *Thielavia terrestris*, *Trametes villosa*, *Trametes versicolor*, *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride* strain cell.

[0135] Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Suitable procedures for transformation of *Aspergillus* and *Trichoderma* host cells are described in EP 238 023 and Yelton et al., 1984, *Proceedings of the National Academy of Sciences USA* 81: 1470-1474. Suitable methods for transforming *Fusarium* species are described by Malardier et al.,

1989, *Gene* 78: 147-156, and WO 96/00787. Yeast may be transformed using the procedures described by Becker and Guarente, In Abelson, J. N. and Simon, M. I., editors, *Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology*, Volume 194, pp 182-187, Academic Press, Inc., New York; Ito et al., 1983, *Journal of Bacteriology* 153: 163; and Hinnen et al., 1978, *Proceedings of the National Academy of Sciences USA* 75: 1920.

#### Methods of Production

[0136] The present invention also relates to methods for producing a polypeptide of the present invention, comprising (a) cultivating a cell, which in its wild-type form is capable of producing the polypeptide, under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide. Preferably, the cell is of the genus *Bacillus*.

[0137] The present invention also relates to methods for producing a polypeptide of the present invention, comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide; and (b) recovering the polypeptide.

[0138] The present invention also relates to methods for producing a polypeptide of the present invention, comprising (a) cultivating a host cell under conditions conducive for production of the polypeptide, wherein the host cell comprises a mutant nucleotide sequence having at least one mutation in the mature polypeptide coding region of SEQ ID NO: 1, wherein the mutant nucleotide sequence encodes a polypeptide which comprises amino acids 1-759 of SEQ ID NO:2, or amino acids 65 to 347 of SEQ ID NO:2 or amino acids 368 to 569 of SEQ ID NO:2, and (b) recovering the polypeptide.

[0139] In the production methods of the present invention, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods well known in the art. For example, the cell may be cultivated by shake flask cultivation, and small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

[0140] The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide as described herein.

[0141] The resulting polypeptide may be recovered using methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.

[0142] The polypeptides of the present invention may be purified by a variety of procedures known in the art including,



but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., *Protein Purification*, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).

[0143] The present invention also relates to isolated enzymes having endo-beta-1,4-glucanase activity and which are produced by one of the above mentioned methods, preferably by recombinant production techniques. The isolated enzymes are preferably free from homologous impurities. Such impurities may arise from endogenous endo-beta-1,4-glucanase genes, hence if production is performed in a host cell which does not express endogenous polypeptides with endo-beta-1,4-glucanase activity, the enzyme will be free of homologous impurities.

#### Compositions

[0144] The present invention also relates to compositions comprising a polypeptide of the present invention. Preferably, the compositions are enriched in such a polypeptide. The term "enriched" indicates that the endoglucanase activity of the composition has been increased, e.g., with an enrichment factor of 1.1.

[0145] The composition may comprise a polypeptide of the present invention as the major enzymatic component, e.g., a mono-component composition. Alternatively, the composition may comprise multiple enzymatic activities, such as an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, haloperoxidase, invertase, laccase, lipase, mannosidase, oxidase, pectinolytic enzyme, peptidoglutaminase, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase. The additional enzyme(s) may be produced, for example, by a microorganism belonging to the genus *Aspergillus*, preferably *Aspergillus aculeatus*, *Aspergillus awamori*, *Aspergillus fumigatus*, *Aspergillus foetidus*, *Aspergillus japonicus*, *Aspergillus nidulans*, *Aspergillus niger*, or *Aspergillus oryzae*; *Fusarium*, preferably *Fusarium bactridioides*, *Fusarium cerealis*, *Fusarium crookwellense*, *Fusarium culmorum*, *Fusarium graminearum*, *Fusarium graminum*, *Fusarium heterosporum*, *Fusarium negundi*, *Fusarium oxysporum*, *Fusarium reticulatum*, *Fusarium roseum*, *Fusarium sambucinum*, *Fusarium sarcochroum*, *Fusarium sulphureum*, *Fusarium toruloseum*, *Fusarium trichothecioides*, or *Fusarium venenatum*; *Humicola*, preferably *Humicola insolens* or *Humicola lanuginosa*; or *Trichoderma*, preferably *Trichoderma harzianum*, *Trichoderma koningii*, *Trichoderma longibrachiatum*, *Trichoderma reesei*, or *Trichoderma viride*.

[0146] The polypeptide compositions may be prepared in accordance with methods known in the art and may be in the form of a liquid or a dry composition. For instance, the polypeptide composition may be in the form of a granulate or a microgranulate. The polypeptide to be included in the composition may be stabilized in accordance with methods known in the art.

[0147] Examples are given below of preferred uses of the polypeptide compositions of the invention. The dosage of the polypeptide composition of the invention and other condi-

tions under which the composition is used may be determined on the basis of methods known in the art.

#### Uses

##### Textile Applications

[0148] In another embodiment, the present invention relates to use of the endoglucanase of the invention in textile finishing processes, such as bio-polishing. Bio-polishing is a specific treatment of the yarn surface which improves fabric quality with respect to handle and appearance without loss of fabric wettability. The most important effects of bio-polishing can be characterized by less fuzz and pilling, increased gloss/luster, improved fabric handle, increased durable softness and altered water absorbency. Bio-polishing usually takes place in the wet processing during the manufacture of knitted and woven fabrics. Wet processing comprises such steps as e.g. desizing, scouring, bleaching, washing, dyeing/printing and finishing. During each of these steps, the fabric is more or less subjected to mechanical action. In general, after the textiles have been knitted or woven, the fabric proceeds to an optional desizing stage, followed by a scouring stage, etc. Desizing is the act of removing size from textiles. Prior to weaving on mechanical looms, warp yarns are often coated with size consisting of starch or starch derivatives in order to increase their tensile strength. After weaving, the size coating must be removed before further processing of the fabric in order to ensure a homogeneous and wash-proof result. In the scouring process impurities are removed from the fabric. The endoglucanase of the invention can advantageously be used in the scouring of cellulosic and cotton textiles, as well as bast fibers and may improve efficiency of removal of impurities.

[0149] One of the most commonly used methods for delivering durable press to cellulosic textiles is via finishing with cellulose crosslinking chemistry. Crosslinking immobilizes cellulose at a molecular level and substantially reduces shrinking and wrinkling of cellulosic garments. Treatment of durable press treated cellulosic textiles with the endo-glucanase of the invention may result in a selective relaxation of stressed regions to minimize edge abrasion. Additionally, the endoglucanase of the invention can be used to efficiently remove excess carboxymethyl cellulose-based print paste from textile and equipment used in the printing process.

[0150] It is known that in order to achieve the effects of bio-polishing, a combination of cellulolytic and mechanical action is required. It is also known that "super-softness" is achievable when the treatment with a cellulase is combined with a conventional treatment with softening agents. It is contemplated that use of the endoglucanase of the invention and of combinations of this enzyme with other enzymes for bio-polishing of cellulose (natural and manufactured cellulose, fabrics, garments, yarns, and fibers) is advantageous, e.g. a more thorough polishing can be achieved. It is believed that bio-polishing may be obtained by applying the method described e.g. in WO 93/20278. It is further contemplated that the endoglucanase of the invention can be applied to simultaneous or sequential textile wet processes, including different combinations of desizing, scouring, bleaching, bio-polishing, dyeing, and finishing.

##### Stone-Washing

[0151] It is known that a "stone-washed" look (localized abrasion of the colour) in dyed fabric, especially in denim fabric or jeans, can be provided either by washing the denim



or jeans made from such fabric in the presence of pumice stones to provide the desired localized lightening of the colour of the fabric or by treating the fabric enzymatically, in particular with cellulytic enzymes. The treatment with an endoglucanase of the present invention, alone or in combination with other enzymes, may be carried out either alone such as disclosed in U.S. Pat. No. 4,832,864, together with a smaller amount of pumice than required in the traditional process, or together with perlite such as disclosed in WO 95/09225. Treatment of denim fabric with the endoglucanase of the invention may reduce backstaining compared to conventional methods.

#### Biomass Degradation

**[0152]** The enzyme or the enzyme composition according to the invention may be applied advantageously e.g. as follows:

**[0153]** For debarking, i.e. pre-treatment with hydrolytic enzymes which may partly degrade the pectin-rich cambium layer prior to debarking in mechanical drums resulting in advantageous energy savings.

**[0154]** For defibration (refining or beating), i.e. treatment of material containing cellulosic fibers with hydrolytic enzymes prior to the refining or beating which results in reduction of the energy consumption due to the hydrolysing effect of the enzymes on the surfaces of the fibers.

**[0155]** For fibre modification, i.e. improvement of fibre properties where partial hydrolysis across the fibre wall is needed which requires deeper penetrating enzymes (e.g. in order to make coarse fibers more flexible).

**[0156]** For drainage: The drainability of papermaking pulps may be improved by treatment of the pulp with hydrolysing enzymes. Use of the enzyme or enzyme composition of to the invention may be more effective, e.g. result in a higher degree of loosening bundles of strongly hydrated micro-fibrils in the fines fraction that limits the rate of drainage by blocking hollow spaces between the fibers and in the wire mesh of the paper machine.

**[0157]** The treatment of lignocellulosic pulp may, e.g., be performed as described in WO 93/08275, WO 91/02839 and WO 92/03608.

#### Laundry

**[0158]** The enzyme or enzyme composition of the invention may be useful in a detergent composition for household or industrial laundering of textiles and garments, and in a process for machine wash treatment of fabrics comprising treating the fabrics during one or more washing cycle of a machine washing process with a washing solution containing the enzyme or enzyme preparation of the invention.

**[0159]** Typically, the detergent composition used in the washing process comprises conventional ingredients such as surfactants (anionic, nonionic, zwitterionic, amphoteric), builders, bleaches (perborates, percarbonates or hydrogen peroxide) and other ingredients, e.g. as described in WO 97/01629 which is hereby incorporated by reference in its entirety.

#### Detergent Applications

**[0160]** The enzyme of the invention may be added to and thus become a component of a detergent composition.

**[0161]** The detergent composition of the invention may for example be formulated as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dish-washing operations, especially for automatic dish washing (ADW).

**[0162]** The endo-beta-1,4-glucanase of the invention provides advantages such as improved stain removal and decreased soil redeposition. Certain stains, for example certain food stains, contain beta-glucans which make complete removal of the stain difficult to achieve. Also, the cellulosic fibres of the fabrics may possess, particularly in the "non-crystalline" and surface regions, beta-glucan polymers that are degraded by this enzyme. Hydrolysis of such beta-glucans, either in the stain or on the fabric, during the washing process decreases the binding of soils onto the fabrics.

**[0163]** Household laundry processes are carried out under a range of conditions. Commonly, the washing time is from 5 to 60 minutes and the washing temperature is in the range 15-60° C., most commonly from 20-40° C. The washing solution is normally neutral or alkaline, most commonly with pH 7-10.5. Bleaches are commonly used, particularly for laundry of white fabrics. These bleaches are commonly the peroxide bleaches, such as sodium perborate, sodium percarbonate or hydrogen peroxide.

**[0164]** In a specific aspect, the invention provides a detergent additive comprising the enzyme of the invention. The detergent additive as well as the detergent composition may comprise one or more other enzymes such as a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, an oxidase, e.g., a laccase, and/or a peroxidase.

**[0165]** In general the properties of the chosen enzyme(s) should be compatible with the selected detergent, (i.e. pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.

Proteases: Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. The protease may be a serine protease or a metallo protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from *Bacillus*, e.g., subtilisin Novo, subtilisin Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the *Fusarium* protease described in WO 89/06270 and WO 94/25583.

**[0166]** Examples of useful proteases are the variants described in WO 92/19729, WO 98/20115, WO 98/20116, and WO 98/34946, especially the variants with substitutions in one or more of the following positions: 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 194, 206, 218, 222, 224, 235 and 274.

**[0167]** Preferred commercially available protease enzymes include Release®, Alcalase®, Savinase®, Primase®, Everlase®, Esperase®, Ovozyme®, Coronase®, Polarzyme® and Kannase® (Novozymes A/S), Maxatase™, Maxacal™, Maxapem™, Properase™, Purafect™, Purafect OXP™,



FN2™, FN3™, FN4™ and Purafect Prime™ (Genencor International, Inc.), BLAP X and BLAP S (Henkel).

Lipases: Suitable lipases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful lipases include lipases from *Humicola* (synonym *Thermomyces*), e.g. from *H. lanuginosa* (*T. lanuginosus*) as described in EP 258 068 and EP 305 216 or from *H. insolens* as described in WO 96/13580, a *Pseudomonas* lipase, e.g. from *P. alcaligenes* or *P. pseudoalcaligenes* (EP 218 272), *P. cepacia* (EP 331 376), *P. stutzeri* (GB 1,372,034), *P. fluorescens*, *Pseudomonas* sp. strain SD 705 (WO 95/06720 and WO 96/27002), *P. wisconsinensis* (WO 96/12012), a *Bacillus* lipase, e.g. from *B. subtilis* (Dartois et al. (1993), *Biochemica et Biophysica Acta*, 1131, 253-360), *B. stearothermophilus* (JP 64/744992) or *B. pumilus* (WO 91/16422).

[0168] Other examples are lipase variants such as those described in WO 92/05249, WO 94/01541, EP 407 225, EP 260 105, WO 95/35381, WO 96/00292, WO 95/30744, WO 94/25578, WO 95/14783, WO 95/22615, WO 97/04079 and WO 97/07202. Preferred commercially available lipase enzymes include Lipolase™ and Lipolase Ultra™ (Novozymes A/S).

Amylases: Suitable amylases ( $\alpha$  and/or  $\beta$ ) include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example,  $\alpha$ -amylases obtained from *Bacillus*, e.g. a special strain of *B. licheniformis*, described in more detail in GB 1,296,839.

[0169] Examples of useful amylases are the variants described in WO 94/02597, WO 94/18314, WO 96/23873, and WO 97/43424, especially the variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 181, 188, 190, 197, 202, 208, 209, 243, 264, 304, 305, 391, 408, and 444.

Commercially used amylases are Duramyl®, Termamyl®, Stainzyme®, Fungamyl® and BAN® (Novozymes A/S), Rapidase™, Purastar™ and Purastar OxAm™ (from Genencor International Inc.).

Cellulases: Other suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera *Bacillus*, *Pseudomonas*, *Humicola*, *Fusarium*, *Thielavia*, *Acremonium*, e.g. the fungal cellulases produced from *Humicola insolens*, *Myceliophthora thermophila* and *Fusarium oxysporum* disclosed in U.S. Pat. No. 4,435,307, U.S. Pat. No. 5,648,263, U.S. Pat. No. 5,691,178, U.S. Pat. No. 5,776,757 and WO 89/09259.

[0170] Especially suitable cellulases are the alkaline or neutral cellulases having colour care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/11262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, U.S. Pat. No. 5,457,046, U.S. Pat. No. 5,686,593, U.S. Pat. No. 5,763,254, WO 95/24471, WO 98/12307 and WO 99/01544.

[0171] Commercially available cellulases include Celuzyme™, Renozyme® and Carezyme™ (Novozymes A/S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation).

Peroxidases/Oxidases: Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from

*Coprinus*, e.g. from *C. cinereus*, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257. Commercially available peroxidases include Guardzyme™ (Novozymes A/S).

Hemicellulases: Suitable hemicellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable hemicellulases include mannanase, lichenase, xylanase, arabinase, galactanase acetyl xylan esterase, glucuronidase, ferulic acid esterase, coumaric acid esterase and arabinofuranosidase as described in WO 95/35362. Suitable mannanases are described in WO 99/64619.

[0172] The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separate additive or a combined additive, can be formulated e.g. as a granulate, a liquid, a slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.

[0173] Non-dusting granulates may be produced, e.g., as disclosed in U.S. Pat. Nos. 4,106,991 and 4,661,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

[0174] The detergent composition of the invention may be in any convenient form, e.g., a bar, a tablet, a powder, a granule, a paste or a liquid. A liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.

[0175] The detergent composition comprises one or more surfactants, which may be non-ionic including semi-polar and/or anionic and/or cationic and/or zwitterionic. The surfactants are typically present at a level of from 0.1% to 60% by weight.

[0176] When included therein the detergent will usually contain from about 1% to about 40% of an anionic surfactant such as linear alkylbenzenesulfonate, alpha-olefinsulfonate, alkyl sulfate (fatty alcohol sulfate), alcohol ethoxysulfate, secondary alkanesulfonate, alpha-sulfo fatty acid methyl ester, alkyl- or alkenylsuccinic acid or soap.

[0177] When included therein the detergent will usually contain from about 0.2% to about 40% of a non-ionic surfactant such as alcohol ethoxylate, nonylphenol ethoxylate, alkylpolyglycoside, alkyl dimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid monoethanolamide, polyhydroxy alkyl fatty acid amide, or N-acyl N-alkyl derivatives of glucosamine ("glucamides").

[0178] The detergent may contain 0-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, carbonate, citrate, nitrilotriacetic



acid, ethylenediaminetetraacetic acid, diethylenetriamine-pentaacetic acid, alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst).

**[0179]** The detergent may comprise one or more polymers. Examples are carboxymethyl-cellulose, poly(vinylpyrrolidone), poly(ethylene glycol), poly(vinyl alcohol), poly(vinylpyridine-N-oxide), poly(vinylimidazole), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

**[0180]** The detergent may contain a bleaching system which may comprise a H<sub>2</sub>O<sub>2</sub> source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetylenediamine or nonanoyloxybenzenesulfonate. Alternatively, the bleaching system may comprise peroxyacids of e.g. the amide, imide, or sulfone type.

**[0181]** The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.

**[0182]** The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bacteriocides, optical brighteners, hydrotropes, tarnish inhibitors, or perfumes.

**[0183]** In the detergent compositions any enzyme, in particular the enzyme of the invention, may be added in an amount corresponding to 0.01-100 mg of enzyme protein per litre of wash liquor, preferably 0.05-5 mg of enzyme protein per litre of wash liquor, in particular 0.1-1 mg of enzyme protein per litre of wash liquor.

**[0184]** The enzyme of the invention may additionally be incorporated in the detergent formulations disclosed in WO 97/07202 which is hereby incorporated as reference.

#### Signal Peptide and Propeptide

**[0185]** The present invention also relates to nucleic acid constructs comprising a gene encoding a protein operably linked to a nucleotide sequence encoding a signal peptide, wherein the gene is foreign to the nucleotide sequence encoding a signal peptide.

**[0186]** The present invention also relates to recombinant expression vectors and recombinant host cells comprising such nucleic acid constructs.

**[0187]** The present invention also relates to methods for producing a protein comprising (a) cultivating such a recombinant host cell under conditions suitable for production of the protein; and (b) recovering the protein.

**[0188]** The first and second nucleotide sequences may be operably linked to foreign genes individually with other control sequences or in combination with other control sequences. Such other control sequences are described supra. As described earlier, where both signal peptide and propeptide regions are present at the amino terminus of a protein, the propeptide region is positioned next to the amino terminus of a protein and the signal peptide region is positioned next to the amino terminus of the propeptide region.

**[0189]** The protein may be native or heterologous to a host cell. The term "protein" is not meant herein to refer to a

specific length of the encoded product and, therefore, encompasses peptides, oligopeptides, and proteins. The term "protein" also encompasses two or more polypeptides combined to form the encoded product. The proteins also include hybrid polypeptides which comprise a combination of partial or complete polypeptide sequences obtained from at least two different proteins wherein one or more may be heterologous or native to the host cell. Proteins further include naturally occurring allelic and engineered variations of the above mentioned proteins and hybrid proteins.

**[0190]** Preferably, the protein is a hormone or variant thereof, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter. In a more preferred aspect, the protein is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase. In an even more preferred aspect, the protein is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase or xylanase.

**[0191]** The gene may be obtained from any prokaryotic, eukaryotic, or other source.

**[0192]** The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.

#### EXAMPLES

**[0193]** Chemicals used as buffers and substrates were commercial products of at least reagent grade.

#### Endoglucanase Activity Assay

##### Materials:

**[0194]** Berol 537, nonionic surfactant supplied by Akzo Nobel, or similar.

Cellazyme C tablets, supplied by Megazyme International, Ireland.

Glass microfiber filters, GF/C, 9 cm diameter, supplied by Whatman.

##### pH9.5 Buffer Solution:

**[0195]** Dissolve 21.0 g of NaHCO<sub>3</sub> and 14.6 g of NaCl in about 900 ml of deionised water. Add 10 ml

Berol 537 (nonionic surfactant supplied by Akzo Nobel). Adjust the pH to 9.5 by addition of 4N NaOH. Then adjust the final volume to 1000 ml.

##### Method:

**[0196]** In test tubes, mix 1 ml pH9.5 buffer and 5 ml deionised water.

Add 100 microliter of the enzyme sample (or of dilutions of the enzyme sample with known weight:weight dilution factor). Add 1 Cellazyme C tablet into each tube, cap the tubes and mix on a vortex mixer for 10 seconds. Place the tubes in a thermostated water bath, temperature 40° C. After 15, 30 and 45 minutes, mix the contents of the tubes by inverting the tubes, and replace in the water bath. After 60 minutes, mix the contents of the tubes by inversion and then filter through a GF/C filter. Collect the filtrate in a clean tubes.



Measure Absorbance ( $A_{enz}$ ) at 590 nm, with a spectrophotometer. A blank value,  $A_{water}$ , is determined by adding 100PI water instead of 100 microliter enzyme dilution.

Calculate  $A_{delta} = A_{enz} - A_{water}$ .

[0197]  $A_{delta}$  must be  $<0.5$ . If higher results are obtained, repeat with a different enzyme dilution factor. Determine DF0.1, where DF0.1 is the dilution factor needed to give  $A_{delta} = 0.1$ .

Unit Definition:

[0198] 1 Endo-Beta-Glucanase activity unit (1 EBG) is the amount of enzyme that gives  $A_{delta} = 0.10$ , under the assay conditions specified above. Thus, for example, if a given enzyme sample, after dilution by a dilution factor of 100, gives  $A_{delta} = 0.10$ , then the enzyme sample has an activity of 100 EBG/g.

Temperature and pH optima of the endoglucanase are determined by running the activity assay at a range of different temperatures when the pH is fixed and vice versa a range of different pH's when the temperature is fixed.

#### Example 1

##### Screening for Novel Endoglucanase

[0199] A number of *Bacillus* strains were screened for production of alkaline endoglucanase by growing the bacteria on TY agar added 0.1% AZCL-beta-glucan (barley, Megazyme). Strain ACE160 produced blue haloes on this substrate, the bacterium was identified by determination of a part of the 16S rDNA, and insertion of the sequence in the phylogenetic tree showed that ACE160 represent a new species with the *Bacillus* group.

#### Example 2

##### Production of Full Length Subtilases

##### Genomic Library Construction

[0200] Chromosomal DNA from ACE160 was prepared by using standard molecular biology techniques (Ausuble et al. 1995 "Current protocols in molecular biology" Publ: John Wiley and sons). The prepared DNA was partially cleaved with Sau3A and separated on an agarose gel. Fragments of 3 to 8 kilobases were eluted and precipitated and resuspended in a suitable buffer.

A genomic library was made by using the Stratagene ZAP Express™ predigested Vector kit and Stratagene ZAP Express™ predigested Gigapack® cloning kit (Bam HI predigested) (Stratagene Inc., USA) following the instructions/recommendations from the vendor. The resulting lambdaZAP library comprised 38000 pfu (plaque forming units) of which 10000 were collected for mass excision. The resulting 70000 *E. coli* colonies were pooled. The *E. coli* clone pool was diluted by mixing 100 µl pool with 100 ml LB medium and plated out 100 µl per agarplate on LB supplemented with 0.1% AZCL.beta-glucan (barley, Megazyme) and 50 µg/ml kanamycin, and incubated for 2-3 days. Among 1600-1800 colonies per plate on 50 agarplates three colonies with blue haloes were obtained. From these three colonies plasmid DNA was recovered and sequenced with vector primers.

By subsequent primer walking the entire nucleotide sequence of the endo-1,4-beta-glucanase open reading frame (ORF) was characterised. The three colonies contained the same ORF shown as SEQ ID NO:1.

##### Production of the Full Length Endoglucanase

[0201] To produce the endo-1,4-beta-glucanase, the gene was amplified from chromosomal DNA of the wild type strain *Bacillus* sp. ACE160. The enzymes were expressed using the indigenous trans membrane signal peptide.

##### Primers

##### [0202]

ACE160-Bglu-Mlu1-4:  
GATTAACGCGTTCCTCGTGCTGAGCACAGAGG (SEQ ID NO: 3)

ACE160-Bglu-Sac1:  
TTATGGAGCTCAAATCAACTCTAGGAGGCTG (SEQ ID NO: 4)

[0203] The endo-1,4-beta-glucanase gene was amplified as a ca. 2500 nt PCR product. The primers ACE160-Bglu-SacI and ACE160-Bglu-Mlu1-4 were used. Template DNA was chromosomal DNA of *Bacillus* sp. ACE160. The PCR product was recovered using Qiaquick™ spin columns as recommended (Qiagen, Germany). The quality of the isolated template was evaluated by agarose gel electrophoresis. PCR was run in the following protocol: 94° C., 2 minutes 40 cycles of [94° C. for 30 seconds, 52° C. for 30 seconds, 68° C. for 1 minute] completed with 68° C. for 10 minutes. PCR product was analysed on a 1% agarose gel in TAE buffer stained with Ethidium bromide to confirm a single band of the correct size. The PCR product was digested with restriction enzymes Sac I and Mlu I and purified on GFX™ PCR and Gel Band Purification Kit (Amerham Biosciences).

[0204] The digested and purified PCR fragment was ligated to the Sac I and Mlu I digested plasmid pDG268NeoMCS-PramyQ/PrCRYIII/cryIIIAstab/Sav (U.S. Pat. No. 5,955,310). The ligation mixture was used for transformation into *E. coli* TOP10F' (Invitrogen BV, The Netherlands) and several colonies were selected for miniprep (QIAprep® spin, QIAGEN GmbH, Germany). The purified plasmids were checked for insert before transformation into *Bacillus subtilis* strain TH1 (TH1 is a *Bacillus subtilis* strain (amy-, spo-, apr-, npr-), that has been modified by insertion of a construct, from the strain DN3 (Noone et al. 2000, J Bacteriol 182 (6) 1592-1599) by transformation and selection for Erythromycin. The changed genotype is: ykdA::pDN3 (PykDA-lacZ Pspac-ykdA) Ermr. TH1 contains the following features: the full ykdA promoter is fused to the LacZ reporter gene. In addition the ykdA gene is placed under control of the IPTG-inducible Pspac promoter, so the ykdA gene no longer has its naturally regulation. The strain can be used as host for expression clones and libraries and transformants expressing and secreting protein can be selected on plates containing X-gal and IPTG. TH1 can be maintained on LB agar+6 µg/mL erythromycin.)

[0205] Transformed cells were plated on LB-PG agar plates, supplemented with 1% skim milk, 100 µg/L X-gal, 1 mM IPTG, 6 µg/ml chloramphenicol and 12 µg/ml erythromycin. The plated cells were incubated over night at 37° C.



and colonies with blue color and without clearing zone were picked, the correct insert was confirmed by PCR and nucleotide sequencing.

### Example 3

#### Purification of the Endoglucanase from *Bacillus* sp. ACE160

[0206] The endoglucanase was purified from 670 ml fermentation broth from which the cells were removed by a combination of centrifugation and filtration of the broth. The volume was adjusted to 21 with deionised water and the pH titrated to 8.5. This material was loaded on a Q-sepharose column equilibrated with 25 mM Tris buffer pH 8.5. The enzyme was eluted by the application of a NaCl gradient in the same buffer and the fractions containing the endoglucanase were pooled. A portion of this pool was fractionated on a S-200 gel-filtration column with 100 mM sodium acetate pH 6 as the liquid phase. The fractions containing the endoglucanase were pooled and concentrated about three times on an Amicon ultrafiltration unit. The concentrate was analysed by SDS PAGE, where a protein band of app. 80 kD was obtained.

### Example 4

#### Wash Performance of Endoglucanase from *Bacillus* sp. ACE160

[0207] This procedure is used to determine the “enzyme detergency benefit”.

[0208] The wash tests are made by washing samples of soiled cotton fabric and samples of clean cotton fabric, both together, in a small-scale wash test apparatus. After the washing the soil on the cotton fabric is evaluated by light reflectance. Both the originally soiled cotton fabric and the originally clean cotton fabric samples are evaluated.

Cotton fabric: #2003 white woven 100% cotton fabric, supplied by Tanigashira, 4-11-15 Komatsu Yodogawa-ku, Osaka, 533-0004, Japan. The new cotton fabric is pre-washed three times before use in the wash test. The pre-washing is done using a European household front-loader washing machine, and using a standard 40° C. wash process. LAS (Surfac® SDBS80 sodium alkylbenzene sulfonate, 80%) is added to the wash water at concentration 0.5 g per liter and the wash solution pH is adjusted to 10 by addition of sodium carbonate. After the pre-washing the fabric is dried in a tumbler drier. Swatches of the pre-washed cotton fabric, size 5×5 cm, weight approximately 0.3 g each, are cut out and these swatches are used for the wash tests.

Soiled cotton swatches: These are prepared from the 5×5 cm swatches described above. Soiled swatches are made using beta-glucan (medium viscosity, from barley, supplied by Megazymes International, Ireland) and carbon black (“carbon for detergency tests”, supplied by Sentaku Kagaku Kyokai, Tokyo, Japan). Dissolve about 0.67 g of beta-glucan in 100 ml tap water by stirring and warming to >50° C. Add 0.33 g carbon black. Blend with an UltraTurrax T25 blender, speed 4000 rpm for 2 minutes. Apply 250 microliter of the beta-glucan/carbon onto the center of each swatch. Allow to dry overnight at room temperature.

Wash tests: Three soiled swatches and three clean swatches are washed in a Mini-Terg-O-Tometer machine. The Mini-Terg-O-Tometer is a small-scale version of the Terg-O-Tometer test washing machine described in Jay C. Harris, “Deter-

gency Evaluation and Testing”, Interscience Publishers Ltd. (1954) pp. 60-61. The following conditions are used:

Beaker size	250 ml
Wash solution volume	100 ml
Wash temperature	40° C.
Wash time	30 minutes
Agitation	150 rpm

The detergent solutions are pre-warmed to 40° C. before starting the test. The fabric and the enzymes are added at the start of the 30 minute wash period. After the wash, the fabric swatches are rinsed for 5 minutes under running tap water, then spread out flat and allowed to air dry at room temperature overnight.

Instrumental evaluations: Light reflectance evaluation of the fabric swatches is done using a Macbeth Color Eye 7000 reflectance spectrophotometer. The measurements are made at 500 nm. The UV filter is not included. Measurements are made on the front and back of each swatch. The soiled swatches are measured in the centre of the soiled area. Average results for reflectance (R, 500 nm) for the soiled swatches and for the clean swatches are then calculated from the six measurements on each type.

Detergent solutions: Detergent solutions are prepared as follows: To prepare 1 liter of solution, dissolve in deionised water 0.5 g sodium carbonate and 1.0 g sodium hydrogen carbonate and add 2 ml of a solution containing 117.8 g/l CaCl<sub>2</sub>·2H<sub>2</sub>O and 54.3 g/l MgCl<sub>2</sub>·6H<sub>2</sub>O. This calcium/magnesium addition provides a water hardness of 12° dH. Add 0.2 g nonionic surfactant (Berol® 537, Akzo Nobel) and 0.5 g LAS (Surfac® SDBS80 sodium alkylbenzene sulfonate, 80%) and adjust the final volume to 1 liter. Adjust the pH to pH 9.5±0.1 (by addition of sodium carbonate or 10% citric acid solution).

Enzyme addition: The enzymes to be tested are pre-dissolved at known concentrations in water, and the required amount of enzyme is added to the detergent solution at the start of the wash process.

Calculation of enzyme detergency benefit: The enzyme detergency benefit is a measure of how much more clean the swatches, both the originally soiled and the originally clean, become as a result of including enzymes in the wash test. The enzyme detergency benefit is calculated as follows:

After the wash test the average R, 500 nm value for the soiled swatches is R, soiled.

After the wash test the average R, 500 nm value for the clean swatches is R, clean.

The enzyme detergency benefit from a wash test with enzymes is the sum of R, soiled+R, clean with enzymes minus the sum of R, soiled+R, clean with no added enzyme.

The enzyme detergency benefit value determined in this way is a combined measure both of the removal of soil from the fabric and of the redeposition of soil onto the fabric. Thus the enzyme detergency benefit value can have values that are negative or positive. The enzyme detergency benefit value can be used to compare the performance of different enzymes. The highest positive detergency benefit value is the preferred result. For comparison, the wash performance of the endoglucanase from *Bacillus* sp. ACE160 was compared with of







-continued

---

gcc atg tat att ggc gaa aat gga tat gcg act aac cct gaa gta aaa Ala Met Tyr Ile Gly Glu Asn Gly Tyr Ala Thr Asn Pro Glu Val Lys 115 120 125	480
gaa ctt gtt tac gaa gga att gag ctt gca ttc aaa cat gat atg tat Glu Leu Val Tyr Glu Gly Ile Glu Leu Ala Phe Lys His Asp Met Tyr 130 135 140	528
gta att gtt gac tgg cac gta cac gcc ccg gga gat cca agg gct gac Val Ile Val Asp Trp His Val His Ala Pro Gly Asp Pro Arg Ala Asp 145 150 155	576
att tat tcc ggt gct cta gac ttt ttt aaa gaa att gca gac cac tat Ile Tyr Ser Gly Ala Leu Asp Phe Phe Lys Glu Ile Ala Asp His Tyr 160 165 170 175	624
aag gac cat cct aag ttc cat tat att ata tgg gaa att gca aat gaa Lys Asp His Pro Lys Phe His Tyr Ile Ile Trp Glu Ile Ala Asn Glu 180 185 190	672
cca agc cca aat aac agc gga gga cct gga att cct aat gat gaa aca Pro Ser Pro Asn Asn Ser Gly Gly Pro Gly Ile Pro Asn Asp Glu Thr 195 200 205	720
gga tgg aaa gca gta aag gaa tat gct gaa cct atc gtg gaa atg ctt Gly Trp Lys Ala Val Lys Glu Tyr Ala Glu Pro Ile Val Glu Met Leu 210 215 220	768
cgt gaa agg ggg gac aat ata att ctt gta ggc agc ccg aac tgg agc Arg Glu Arg Gly Asp Asn Ile Ile Leu Val Gly Ser Pro Asn Trp Ser 225 230 235	816
cag cgc ccg gat tta gct gca gat aac cct ata gat gca aaa aat atc Gln Arg Pro Asp Leu Ala Ala Asp Asn Pro Ile Asp Ala Lys Asn Ile 240 245 250 255	864
atg tac tct gtc cac ttc tat act gga tct cat gaa cct tca gat aca Met Tyr Ser Val His Phe Tyr Thr Gly Ser His Glu Pro Ser Asp Thr 260 265 270	912
agc tat cct gaa ggc act ccg tcc tcg gaa cgg aat aac gtt atg gca Ser Tyr Pro Glu Gly Thr Pro Ser Ser Glu Arg Asn Asn Val Met Ala 275 280 285	960
aat gta cga tat gca ctc gag aat ggt gct gca gtt ttt gct aca gaa Asn Val Arg Tyr Ala Leu Glu Asn Gly Ala Ala Val Phe Ala Thr Glu 290 295 300	1008
tgg ggt aca agc caa gcc aat ggt gat ggc ggc cca tac ctt gac gaa Trp Gly Thr Ser Gln Ala Asn Gly Asp Gly Gly Pro Tyr Leu Asp Glu 305 310 315	1056
gct gat gta tgg ctt aac ttc ctt aac gag aac aat atc agc tgg gtc Ala Asp Val Trp Leu Asn Phe Leu Asn Glu Asn Asn Ile Ser Trp Val 320 325 330 335	1104
aac tgg tca ttg aca aat aaa aac gaa aca tca ggt tcc ttc act ccc Asn Trp Ser Leu Thr Asn Lys Asn Glu Thr Ser Gly Ser Phe Thr Pro 340 345 350	1152
ttt gag ctg ggg aaa tcc aat gcc aca agt ctt gat cct ggc cct gaa Phe Glu Leu Gly Lys Ser Asn Ala Thr Ser Leu Asp Pro Gly Pro Glu 355 360 365	1200
caa gca tgg tcc ctg ccg gaa cta agc gta tca ggc gag tat gtt cgt Gln Ala Trp Ser Leu Pro Glu Leu Ser Val Ser Gly Glu Tyr Val Arg 370 375 380	1248
tca cga att aaa ggt agt ccg tat gaa ccg ttt gac cgg acg aaa ttt Ser Arg Ile Lys Gly Ser Pro Tyr Glu Pro Phe Asp Arg Thr Lys Phe 385 390 395	1296
aat aaa gta atc tgg gat ttt aac gac ggt aca gtt cag ggg ttt gaa Asn Lys Val Ile Trp Asp Phe Asn Asp Gly Thr Val Gln Gly Phe Glu 400 405 410 415	1344



-continued

---

gta aat gac gac agt cct gtt aaa gaa gaa ata gct gtc agc aat gca	1392
Val Asn Asp Asp Ser Pro Val Lys Glu Glu Ile Ala Val Ser Asn Ala	
420 425 430	
ggt aat gcc ctt caa att acc ggt ctt aat gct agc aac gac atc tcc	1440
Gly Asn Ala Leu Gln Ile Thr Gly Leu Asn Ala Ser Asn Asp Ile Ser	
435 440 445	
aca gat aac ttc tgg agt aac ctc agg ctt tca gcc aat tcc tgg gga	1488
Thr Asp Asn Phe Trp Ser Asn Leu Arg Leu Ser Ala Asn Ser Trp Gly	
450 455 460	
gaa tcg gtt aat atc ctg ggg gca gaa gaa ctg aca tta gat gtg atc	1536
Glu Ser Val Asn Ile Leu Gly Ala Glu Glu Leu Thr Leu Asp Val Ile	
465 470 475	
gtc gat gag cca act tcc gtc tca atc gca gca att ccg caa agt gca	1584
Val Asp Glu Pro Thr Ser Val Ser Ile Ala Ala Ile Pro Gln Ser Ala	
480 485 490 495	
gca gtt ggc tgg gca aat cct aac aat gcg gtc gtt gtt tct aaa gaa	1632
Ala Val Gly Trp Ala Asn Pro Asn Asn Ala Val Val Val Ser Lys Glu	
500 505 510	
gat ttc gca cct tat ggt ggc cag tat aag gct gtc ctg acg ata aca	1680
Asp Phe Ala Pro Tyr Gly Gly Gln Tyr Lys Ala Val Leu Thr Ile Thr	
515 520 525	
ccg gaa gat tct cca gct ctg ggt gcc ata gca aca cat agt gat gat	1728
Pro Glu Asp Ser Pro Ala Leu Gly Ala Ile Ala Thr His Ser Asp Asp	
530 535 540	
aac atg atg aat aac att atc ttg ttt ata ggt aca gaa aat gct gat	1776
Asn Met Met Asn Asn Ile Ile Leu Phe Ile Gly Thr Glu Asn Ala Asp	
545 550 555	
gta ctc tca ctt gat aac att aca gtt aaa ggt tcc atc gtt gaa att	1824
Val Leu Ser Leu Asp Asn Ile Thr Val Lys Gly Ser Ile Val Glu Ile	
560 565 570 575	
cca gta atc cat gat cca aag ggc atc gcg gtt ctt cct tca aac ttt	1872
Pro Val Ile His Asp Pro Lys Gly Ile Ala Val Leu Pro Ser Asn Phe	
580 585 590	
gag gac gga acc cgc caa ggc tgg gac tgg aac cct gaa tca ggg gta	1920
Glu Asp Gly Thr Arg Gln Gly Trp Asp Trp Asn Pro Glu Ser Gly Val	
595 600 605	
aaa act gct tta aca att aaa gag gcc gat ggt tca cat gcc cta tcc	1968
Lys Thr Ala Leu Thr Ile Lys Glu Ala Asp Gly Ser His Ala Leu Ser	
610 615 620	
tgg gag ttt gct tac ccg gaa gtt aaa cct ggt gat ggg tgg gca aca	2016
Trp Glu Phe Ala Tyr Pro Glu Val Lys Pro Gly Asp Gly Trp Ala Thr	
625 630 635	
gct cca cga ttg gag ttt tgg aaa gat gga ctg gta aga gga gca aac	2064
Ala Pro Arg Leu Glu Phe Trp Lys Asp Gly Leu Val Arg Gly Ala Asn	
640 645 650 655	
gat tac ctc tca ttt gat tta tac ctt gac cct gtc cgt gcc aca gag	2112
Asp Tyr Leu Ser Phe Asp Leu Tyr Leu Asp Pro Val Arg Ala Thr Glu	
660 665 670	
ggt gct atc aca aca cat ctc gta ttc cag ccg cca agt gct gga tac	2160
Gly Ala Ile Thr Thr His Leu Val Phe Gln Pro Pro Ser Ala Gly Tyr	
675 680 685	
tgg gta caa gct cca gct tct cac agc ata gat ttg tta aac tta gat	2208
Trp Val Gln Ala Pro Ala Ser His Ser Ile Asp Leu Leu Asn Leu Asp	
690 695 700	
tca gct gat atc aca gca gat gga ctg tac cat tat gaa gtg aaa ttc	2256
Ser Ala Asp Ile Thr Ala Asp Gly Leu Tyr His Tyr Glu Val Lys Phe	
705 710 715	



-continued

---

```

aat att aga gac att aca gca att caa gat gac aca gct ctg cgc aat      2304
Asn Ile Arg Asp Ile Thr Ala Ile Gln Asp Asp Thr Ala Leu Arg Asn
720                725                730                735

```

```

atg atc ctc ata ttg gag gat agg aac agc gac ttc gcg ggc cgg gcg      2352
Met Ile Leu Ile Leu Glu Asp Arg Asn Ser Asp Phe Ala Gly Arg Ala
740                745                750

```

```

ttc atc gac aat gta aga ttc gaa taa      2379
Phe Ile Asp Asn Val Arg Phe Glu
755

```

```

<210> SEQ ID NO 2
<211> LENGTH: 792
<212> TYPE: PRT
<213> ORGANISM: Bacillus sp. ACE160

```

```

<400> SEQUENCE: 2

```

```

Val Arg Gln Pro Ile Gly Lys Lys Ile Ile Ala Ala Gly Met Ile Phe
-30                -25                -20

```

```

Thr Leu Leu Phe Ser Leu Ile Val Thr Val Phe Pro Thr Ala Gly Gln
-15                -10                -5

```

```

Ala Leu Glu Ser Asp Tyr Ser His Leu Leu Gly Asn Asp Ala Val Lys
-1  1                5                10                15

```

```

Arg Pro Ser Glu Gly Gly Ala Leu Ser Leu Cys Asn Glu Thr Thr Pro
20                25                30

```

```

Val Lys Pro Asn His Ala Gly Asp Arg Gly Lys Pro Ser His Ala Gly
35                40                45

```

```

Lys Gly Lys Pro Pro His Ala Gly Lys Pro Glu His Ala Gly Pro Lys
50                55                60

```

```

Arg Lys Thr Leu Cys Asp Ala Thr Gly Ser Gln Ile Gln Leu Arg Gly
65                70                75

```

```

Met Ser Thr His Gly Leu Gln Trp Phe Gly Glu Ile Ile Asn Asp Asn
80                85                90                95

```

```

Ala Phe Ala Ala Leu Ser Asn Asp Trp Glu Ala Asn Met Ile Arg Leu
100                105                110

```

```

Ala Met Tyr Ile Gly Glu Asn Gly Tyr Ala Thr Asn Pro Glu Val Lys
115                120                125

```

```

Glu Leu Val Tyr Glu Gly Ile Glu Leu Ala Phe Lys His Asp Met Tyr
130                135                140

```

```

Val Ile Val Asp Trp His Val His Ala Pro Gly Asp Pro Arg Ala Asp
145                150                155

```

```

Ile Tyr Ser Gly Ala Leu Asp Phe Phe Lys Glu Ile Ala Asp His Tyr
160                165                170                175

```

```

Lys Asp His Pro Lys Phe His Tyr Ile Ile Trp Glu Ile Ala Asn Glu
180                185                190

```

```

Pro Ser Pro Asn Asn Ser Gly Gly Pro Gly Ile Pro Asn Asp Glu Thr
195                200                205

```

```

Gly Trp Lys Ala Val Lys Glu Tyr Ala Glu Pro Ile Val Glu Met Leu
210                215                220

```

```

Arg Glu Arg Gly Asp Asn Ile Ile Leu Val Gly Ser Pro Asn Trp Ser
225                230                235

```

```

Gln Arg Pro Asp Leu Ala Ala Asp Asn Pro Ile Asp Ala Lys Asn Ile
240                245                250                255

```

```

Met Tyr Ser Val His Phe Tyr Thr Gly Ser His Glu Pro Ser Asp Thr

```







-continued

---

Gly Ala Ile Thr Thr His Leu Val Phe Gln Pro Pro Ser Ala Gly Tyr  
675 680 685

Trp Val Gln Ala Pro Ala Ser His Ser Ile Asp Leu Leu Asn Leu Asp  
690 695 700

Ser Ala Asp Ile Thr Ala Asp Gly Leu Tyr His Tyr Glu Val Lys Phe  
705 710 715

Asn Ile Arg Asp Ile Thr Ala Ile Gln Asp Asp Thr Ala Leu Arg Asn  
720 725 730 735

Met Ile Leu Ile Leu Glu Asp Arg Asn Ser Asp Phe Ala Gly Arg Ala  
740 745 750

Phe Ile Asp Asn Val Arg Phe Glu  
755

<210> SEQ ID NO 3  
<211> LENGTH: 32  
<212> TYPE: DNA  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 3

gattaacgcg ttctctcgtgc tgagcacaga gg

32

<210> SEQ ID NO 4  
<211> LENGTH: 31  
<212> TYPE: DNA  
<213> ORGANISM: Artificial sequence  
<220> FEATURE:  
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 4

ttatggagct caaatcaact ctaggaggct g

31

---

**1-20.** (canceled)

**21.** An isolated polypeptide having endoglucanase activity, selected from the group consisting of:

- a) a polypeptide having an amino acid sequence which has at least 72% identity with amino acids 1 to 759 of SEQ ID NO: 2;
- b) a polypeptide having an amino acid sequence which has at least 86% identity with amino acids 65 to 347 of SEQ ID NO: 2;
- c) a polypeptide which is encoded by a polynucleotide which hybridizes under at least low stringency conditions with (i) nucleotides 100 to 2376 of SEQ ID NO: 1, (ii) nucleotides 193 to 1041 of SEQ ID NO: 1, or (iii) a complementary strand of (i) or (ii);
- d) a variant comprising a conservative substitution, deletion, and/or insertion of one or more amino acids of amino acids 1 to 759 of SEQ ID NO: 2;
- e) a polypeptide encoded by a nucleotide sequence which comprises nucleotides 100 to 2376 of SEQ ID NO: 1 or nucleotides 193 to 1041 of SEQ ID NO: 1.

**22.** The polypeptide of claim **21**, which comprises amino acids 368 to 569 of SEQ ID NO: 2 has carbohydrate binding module activity.

**23.** The polypeptide of claim **21**, which has at least one of the following properties:

- a) a pI of 4.4,
- b) a pH optimum of 9,
- c) a temperature optimum of 40° C., or
- d) stability at pH from 5 to 10.5.

**24.** An enzyme composition comprising a polypeptide of claim **21**.

**25.** The composition of claim **24**, which further comprises one or more enzymes selected from the group consisting of proteases, cellulases, endoglucanases, beta-glucanases, hemicellulases, lipases, peroxidases, laccases, alpha-amylases, glucoamylases, cutinases, pectinases, reductases, oxidases, phenoloxidasases, ligninases, pullulanases, pectate lyases, xyloglucanases, xylanases, pectin acetyl esterases, polygalacturonases, rhamnogalacturonases, pectin lyases, mannanases, pectin methylesterases, cellobiohydrolases, transglutaminases; or mixtures thereof.

**26.** A detergent composition comprising a polypeptide of claim **21** and a surfactant.

**27.** A textile treatment composition comprising a polypeptide of claim **21**.



**28.** A method for degradation of cellulose-containing biomass, comprising treating the biomass with an effective amount of a polypeptide of claim **21**.

**29.** An isolated polynucleotide comprising a nucleotide sequence which encodes the polypeptide of claim **24**.

**30.** The polynucleotide of claim **29**, having at least one mutation in the mature polypeptide coding sequence of SEQ ID NO: 1, in which the mutant nucleotide sequence encodes a polypeptide consisting of amino acids 1 to 759 of SEQ ID NO: 2.

**31.** An isolated polynucleotide hybridizing under at least low stringency conditions with (a) nucleotides 100 to 2376 of SEQ ID NO: 1, (b) nucleotides 193 to 1041 of SEQ ID NO: 1, (c) nucleotides 1104 to 1707 of SEQ ID NO: 1, or (d) a complementary strand of (a), (b) or (c).

**32.** A nucleic acid construct comprising the polynucleotide of claim **29** operably linked to one or more control sequences that direct the production of the polypeptide in an expression host.

**33.** A recombinant expression vector comprising the nucleic acid construct of claim **32**.

**34.** A recombinant host cell comprising the nucleic acid construct of claim **32**.

**35.** A method for producing the polypeptide having endoglucanase activity, comprising

(a) cultivating a host cell of claim **34**; and

(b) recovering the polypeptide.

\* \* \* \* \*